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Abstract: The 90 kDa heat shock proteins (Hsp90) are molecular chaperones that are 
upregulated in response to cellular stress and are responsible for th conformational maturation, 
activation and/or stability of more than 200 client proteins.  Many of these clients are oncogenic 
and facilitate the progression of cancer.  Disruption of Hsp90’s inhere t ATPase activity renders 
the chaperone inactive, leading to degradation of substrates and ultimately, apoptosis.  
Consequently, Hsp90 has become a highly sought after anti-cancer targ t and numerous 
pharmaceutical companies and academic labs are expending efforts to develop novel methods to 
regulate the Hsp90-mediated protein folding process.   
Included within the Hsp90 family are four isoforms, each of which exibits a unique 
cellular localization, expression, function and clientele.  Hsp90α (inducible) and Hsp90β 
(constitutive) both localize to the cytoplasm and share similar functions; however, recent studies 
have identified isoform specific substrates.  Tumor necrosis factor receptor-associated protein 
(TRAP-1) is the Hsp90 isoform localized to the mitchondria and to date, no specific clients or 
selective inhibitors have been identified.  The fourth isoform is glucose-regulated protein 94 kDa 
(Grp94), which is localized to the endoplasmic reticulum and is responsible for the maturation 
and stability of specific secreted and membrane bound proteins.  Currently identified Hsp90 
inhibitors exhibit pan-inhibition, resulting in the disruption of all four isoforms’ ability to bind 
and hydrolyze ATP.  This activity is believed responsible for the undesired toxicities related to 
Hsp90 inhibition in the clinic, as proteins that are critical to cardio function and the central 
nervous system are dependent upon yet to be determined Hsp90 isoforms.  
Another detriment arising from N-terminal Hsp90 inhibition is induction of the pro-
survival, heat shock response.  Specifically, induction of the target, Hsp90, has resulted in 
therapeutic resistance and complications with dosing and administration protocols. 
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Presented herein is rationale for the development of Hsp90 isoform selective inhibitors 
and the first irreversible inhibitor of Hsp90 that mitigates induction of Hsp90; thus, providing 
key advancements towards addressing the detriments associated with Hsp90 inhibitors currently 
under clinical investigation.  
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A New Generation of Hsp90 Inhibitors: 
Addressing Isoform Selectivity and Heat Shock Induction 
 1
Chapter I 
 
An Introduction to Hsp90 and Hsp90 Inhibitors Under Clinical Evaluation 
 
I.1 Molecular Chaperones 
 The ability of organisms to maintain a cellular environment consistent with vitality and 
well-being is referred to as homeostasis.  Multiple pathways regulate cellular homeostasis, many 
of which consist of feedback mechanisms that are critical to maintaining a viable cellular 
environment.  One of the most important aspects of cellular homeostasis is the abili y to maintain 
the conformation of intracellular proteins, which encompasses their fold ng, stability, activation, 
trafficking and degradation.  This maintenance is provided by a group of unrelated protein 
families referred to as molecular chaperones.1-6 
    As essential components of cellular viability, molecular chaperones respond to cellular 
stress, and mitigate the effects of extra- or intra-cellular stressors.  Molecular chaperones interact 
with unfolded or partially folded proteins, to expedite the formation of bi logically active 
structures, or remove the denatured substrates via degradation mechanisms.  Proteins that depend 
upon or interact with molecular chaperones are termed clients, and each molecular chaperone 
interacts with a unique set of clients, with some chaperones exhibiting more selectivity than 
others.3, 5  One class of molecular chaperone that has recently received significant attention is the 
heat shock protein family (HSP).  Consistent with the name of this class, HSP expression is 
increased upon cellular stress, including elevated temperatures.  However, induction can also 
result upon toxic insult,7 inflammation,8 hypoxia,9 infection,10 and/or nutrient starvation.11  The 
increase of HSPs is a major constituent of the heat shock response (HSR), which is activated 
through the transcription factor, heat shock factor-1 (HSF-1), and the heat shock element (HSE), 
resulting in gene upregulation.12 
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 The HSP family 
consists of multiple members 
that are named according to 
their molecular weight.  For 
example, Hsp90 refers to a 
subset of heat shock proteins 
with a molecular weight of 
~90 kDa.  The principle HSPs 
are presented in Table 1.  The upregulation of HSPs in response to cellular stressors has led to 
their implication in the progression of many disease states, highlighting their potential 
chemotherapeutic utility.4, 13, 14 
I.2 Heat Shock Protein 90 kDa 
 Heat shock protein 90 kDa (Hsp90) is one of the most abundant ATPases in eukaryotic 
organisms, comprising ~1-2% of total cellular protein under non-stressed conditions.15, 16  Upon 
introduction of stress, intracellular Hsp90 is increased to ~4-6% of total protein concentration.16  
In unstressed cells, Hsp90 exists in a latent state and aids homeostasis through transient protein 
folding assistance, intracellular transport, maintenance and degradation.  Under stressed 
conditions, especially in malignancies, Hsp90 is upregulated to handle the increased demand of 
client proteins for the conformationally viable states induced by the chaperone. Furthermore, in 
stressed conditions, Hsp90 exists in a heteroprotein complex that ex ibits higher affinity for 
ATP.17  Thus, the prevalence of a high-affinity state, an addiction of cancer cells to oncogenic 
client proteins, and a greater dependency upon Hsp90 have supported Hsp90 inhibition as a 
novel chemotherapeutic target for the treatment of cancer.18-21  In addition, Hsp90 is responsible 
Table 1:  Principle heat shock proteins. 
Family Localization Function(s) 
Small Hsps (12-43 
kDa) 
cytosol 
general chaperone, co-
factor 
Hsp60 
mitochondria, cytosol, 
extracellular 
mitochondrial protein 
folding 
Hsp70 
cytosol, lysosome, 
mitochondria 
protein folding 
Hsp90 
cytosol, mitochondria, 
endoplasmic 
reticulum, 
extracellular 
protein folding, 
activation, 
stabilization, cell 
signaling 
Hsp100 mitochondria 
solubilization of 
protein aggregates 
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for clientele that maintain critical roles in all six hallmarks of cancer (Figure 1).22-24  Therefore, 
Hsp90 inhibition results in simultaneous disruption of all six events that are necessary for 
oncogenesis.25 
I.2.1 Architecture and Energy Requirements of Hsp90 
 Hsp90 chaperones exist as homodimers, with each monomer consisting of an N-terminal 
regulatory domain (NTD), a charged linker (CL), a middle domain (MD) and a C-terminal 
dimerization domain (CTD) (Figure 2).16  Hsp90 chaperone activity is linked to an ATP-driven 
conformational change within the NTD, leading to the closure of a helix-loop-helix “lid” over 
the ATP binding pocket.26  This lid closure allows for a transient NTD dimerization that 
stabilizes alignment of the catalytic residues from the NTD and MD of the protein, resulting in 
ATP hydrolysis.27  
 Hsp90 is a member of the GHKL superfamily, which consists of DNA Gyrase, Hsp90, 
Histidine Kinase and Mut L.  This superfamily contains a Bergerat-type ATP-binding domain 
Raf , Her2
CDK4
CDK6
MET
MMP2
hTERT
VEGF
VEGFR
HIF-1
AKT
RIP
Survivin
 
Figure 1.  Six hallmarks of cancer.  Example Hsp90 clients involved in each 
hallmark are listed in orange.23 
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that binds nucleotides in a bent conformation, which is in contrast to other ATPases that bind 
nucleotides in a linear fashion.  Mut L and Histidine kinase represnt the other two members of 
this class expressed in the human genome.28  Thus, Hsp90 inhibitors exhibit excellent selectivity 
due to the unique binding geometry not accommodated by other ATPases. 
As shown in Figure 2, nascent polypeptides are delivered to the Hsp90 homodimer via 
heat shock proteins 70 kDa (Hsp70) and 40 kDa (Hsp40) along with Hsp70/Hsp90 organizing 
protein (Hop).29  Upon transfer of the substrate (client) to Hsp90 (1.2),30 client-dependent 
immunophilins and co-chaperones associate with the complex to form the activated heteroprotein 
complex (1.3).27  This activated complex exhibits a high affinity for N-terminal ligands, 
including ATP and competitive inhibitors.17  Upon binding ATP, N-terminal dimerization (1.4) 
occurs,26 followed by the binding of p23, which facilitates the hydrolysis of ATP to ADP (1.5).31  
This hydrolysis provides the requisite energy for client folding, which yields the biologically 
active client (1.6), and releases Hsp90 (1.1) for future catalytic turnover.27, 32  Introduction of a 
((
Figure 2. Hsp90 protein folding cycle.32 
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competitive ATP-inhibitor, arrests the substrate bound complex (1.7), resulting in 
ubiquitinylation of the client and subsequent degradation via the proteasome.33, 34 
I.2.2 Hsp90 Isoforms 
 Four isoforms of Hsp90 are expressed in the human genome including cytoplasmic 
Hsp90α (inducible) and Hsp90β (constitutive); tumor necrosis factor receptor-associated protein 
(TRAP-1), which is localized to the mitochondria; and glucose-regulated protein (Grp94), which 
is localized to the endoplasmic reticulum.35, 36  Similarities between the isoforms include 1) 
native existence as obligate homodimers; 2) dependence upon ATP-binding a  hydrolysis; 3) a 
characteristic Bergerat-fold N-terminal ATP-binding pocket and 4) similar architecture including 
a NTD, MD and CTD.37  However, amongst the isoforms differences have been observed, which 
has led to investigations aimed at elucidating the biological roles of each isoform.  
Cytosolic Hsp90α and Hsp90β 
Cytosolic Hsp90 has received the most attention from the Hsp90 research community. 
Numerous crystal and co-crystal structures have been solved for the cytosolic forms of Hsp90 
and the list of identified clients continues to grow.  Substrates of cyt solic Hsp90 encompass a 
vast array of proteins necessary for cellular function including protein kinase signaling proteins 
(Her2, Raf, Akt), mutated signaling proteins (p53, Kit, TK3), transcription factors (steroid 
hormone receptors: GR, AR), angiogenic factors (HIF–1α), telomerase, and cell-cycle regulators 
(CDK4 and CDK6).22  As such, cytosolic Hsp90 is responsible for the conformational maturation 
of enzymes implicated in all six hallmarks of cancer (Figure 1).  Thus, it was hypothesized that 
inhibition of cytosolic Hsp90 would result in simultaneous disruption of all six hallmarks of 
cancer, providing a ‘magic bullet’ chemotherapeutic target.  However, no Hsp90 inhibitor has 
been approved by the FDA at present.  
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Hsp90α and Hsp90β exhibit ~95 % sequence homology at the ATP-binding region,36 
which has limited the potential for designing Hsp90α versus Hsp90β isoform selective inhibitors.  
With the lack of isoform specific inhibitors, it has been difficult to identify isoform dependent 
clients.  However, function and expression profiles of the two paralogs have been analyzed 
through siRNA techniques.  Constitutively active Hsp90β maintains key roles in early embryonic 
development, germ cell maturation, cytoskeletal stabilization, cellular transformation, signal 
transduction and long-term cell adaptation.  In contrast, the inducible form, Hsp90α, is essential 
for the promotion of growth, cell cycle regulation and stress-induced cytoprotection.37  Specific 
cellular functions of the two isoforms, suggest that each interacts with a unique subset of client 
proteins and co-chaperones.  As a consequence, the client proteins and co-chaperones proposed 
to interact with “cytosolic Hsp90” are undergoing more thorough investigation to identify which 
isoforms they interact with.  For this reason, the abbreviation, Hsp90 i accepted to encompass 
both cytosolic isoforms and will be used in this manner for the remainder of this dissertat on.  
Mitchondrial TRAP-1 
 Tumor necrosis factor (TNF) receptor-associated protein 1 (TRAP-1) was discovered 
upon its interaction with the intracellular domain of type 1 TNF receptor (TNFR-1).38  
Subsequent characterization of TRAP-1 showed ~35% identity and ~50% overall simil rity with 
cytosolic Hsp90, and a ~70% similarity of the N-terminal ATP binding domain.38, 39  
Furthermore, several known N-terminal inhibitors of cytosolic Hsp90 (discussed in-depth in 
section I.2.3) also competitively inhibit ATP binding to TRAP-1.40  In addition, every amino acid 
shown via mutational analysis to be essential for ATP binding to Hsp90 is conserved in the 
TRAP-1 N-terminal ATP-binding pocket.35, 36  Thus, due to the structural conservation at the N-
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terminal binding pocket, no TRAP-1 selective small molecule inhibitor has been developed to 
date. 
 Structurally, TRAP-1 lacks the charged linker connecting the N-t rminal and middle 
domains noted in cytosolic Hsp90.  Furthermore, TRAP-1 only exhibits ~23% identity with 
cytosolic Hsp90 in the C-terminal domain35 and lacks the MEEVD tetratricopeptide repeat 
region responsible for the interactions with many co-chaperones.  Thus, it is not surprising that 
TRAP-1 fails to interact with cytosolic Hsp90 co-chaperones including tumor suppressor p23 
and Hop.39  Therefore, it is hypothesized that TRAP-1 exhibits unique cellular f nctions and 
interacts with a specific set of client proteins and co-chaperones distinct from those that interact 
with cytosolic Hsp90.  Identification of TRAP-1 selective inhibitors would be instrumental in 
delineating the biological function of this Hsp90 isoform.  However, to date, no solution, crystal 
or co-crystal structures have been solved for TRAP-1, which has made structure-based ligand 
design difficult. 
Endoplasmic Reticulum Localized Grp94  
 Glucose-regulated protein 94 kDa (Grp94) was first reported in 1977 upon the 
observation that its induction coincided with glucose deprivation.41  Subsequent studies have 
revealed additional functions of Grp94 leading to alternative names such as gp96 and 
endoplasmin.42  Unlike TRAP-1, co-crystal structures of Grp94 have been solved; however, no 
selective small molecule inhibitors have been developed. 
 Structurally, Grp94 exhibits ~50% overall identity with cytosolic Hsp90 in the N-
terminal domain; nonetheless, the amino acids required for ligand binding are completely 
conserved.43  The primary sequence for Grp94, however, contains a 3–5 species-dependent 
amino acid insertion, which has been shown to perturb the tertiary structure of the N-terminal 
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ATP-binding pocket.43  This perturbation may provide an opportunity for ligand selectivity and
is therefore hypothesized for use in the design of selective inhibitors.  As with TRAP-1, Grp94 
also lacks the TPR domain required for interaction with cytosolic Hsp90 co-chaperones, which 
suggests Grp94 operates under a unique regulatory mechanism and interacts with a distinct set of 
client proteins.44, 45   
Recently, Grp94 has garnered considerable attention for its involvement in the biological 
maturation of secretory and membrane proteins including Toll-like recptors, integrins and 
growth factors.46  Furthermore, Grp94 has been implicated in apoptosis protection,47 cancer 
progression,48 immunomodulation46 and drug resistance.49  Thus, Grp94 has garnered the 
attention of the Hsp90 community as a novel target for diseases ranging from cancer to 
immunological conditions.  Grp94 is discussed in detail in Chapter III.     
I.2.3 Natural Product Inhibitors of Hsp90 
 Known inhibitors of Hsp90 ATPase activity (Figure 3) include the natural p oducts 
geldanamycin (GDA) and radicicol (RDC).  Geldanamycin, a benzoquinone ansamycin 
antibiotic, was first isolated from the broth of Streptomyces hygroscopicus during the 1970s.50  
The first antitumor activity for GDA was reported nearly 20 years later, and the mode of action 
was believed to result from tyrosine kinase inhibition, 
due to its ability to reverse v-Src transformed cells into 
normal phentoypes.51, 52  Subsequent studies revealed 
GDA to bind the N-terminal ATP-binding site of Hsp90, 
resulting in disruption of v-Src’s maturation.53 
Radicicol, a natural product that maintains 
antifungal properties, was originally isolated from the 
 
Figure 3.  Natural product 
inhibitors of Hsp90. 
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fungus Monosporium bonorden in 1953.54  Subsequent studies revealed RDC to be a potent 
inhibitor of Hsp90 through competitive inhibition of the N-terminal ATP-binding domain.55, 56  
The identification of GDA and RDC as potent natural product inhibitors of the Hsp90 N-terminal 
binding domain has been instrumental towards the delineation of the biological functions 
manifested by Hsp90 and for the facilitation of small molecule Hsp90 inhibitor development.   
The co-crystal structures of adenosine nucleotides, GDA and RDC with Hsp90 have been 
solved, and have elucidated the key interactions of each ligand in the N-terminal nucleotide-
binding pocket (Figure 4).  The co-crystal structure of GDA bound to Hsp90 revealed the 
quinone moiety of GDA to occupy the diphosphate region of the binding pocket and to provide 
five hydrogen-bonding interactions with the protein (B, Figure 4).57  In contrast, the 2,4-diphenol 
of RDC occupies the binding region normally occupied by the adenine ring of ATP, producing 
three important hydrogen-bonding interactions with Hsp90 (C, Figure 4). The chlorine atom in 
RDC projects into a large hydrophobic cavity that is surrounded by aromatic amino acids.57  
Unlike the quinone ring of GDA, only one hydrogen bond is formed between the oxirane of 
RDC and the phosphate-binding region.57  Although GDA and RDC show no obvious structural 
compatibility with Hsp90’s endogenous ligand, ATP, each natural product binds with high 
affinity through a network of specific hydrogen bonding interactions.  Thus, both natural 
products have served as templates for the design of Hsp90 inhibitors; even though the biological 
profile exhibited by GDA and RDC limits their clinical utility. 
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GDA produces toxicity unrelated to Hsp90 inhibition and suffers from poors lubility.58-
61 Quinones are redox-active and recent studies have shown GDA to be a su strate for P-450 
reductases.62, 63 Upon reduction by these enzymes, GDA is converted to a semiquinone a d upon 
A B
C
ADP
GDA
RDC
 
Figure 4.  Schematic depictions of ligand interactions with the N-terminal domain of Hsp90.  
A) ADP, B) GDA, and C) RDC.57   
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exposure to oxygen, generates superoxide radicals.62, 63 Superoxide radicals cause cell death in an 
Hsp90-independent manner. Therefore, new Hsp90 inhibitors lacking redox-active 
functionalities are being pursued to circumvent these effects. 
In contrast to GDA, RDC lacks in vivo activity, despite its higher affinity for the N-
terminal ATP-binding domain (GDA: Kd = 1.2 µM / RDC: Kd = 19 nM).
57 In vivo, the 
electrophilic nature of the α,β,γ,δ–unsaturated carbonyl moiety and the allylic epoxide result in 
rapid conversion to inactive compounds that have little or no affinity for Hsp90.64, 65  
Replacement of the epoxide ring of RDC with a cyclopropane moiety r sulted in 
cycloproparadicicol, which displays potent activity against several cancer cell lines and is being 
investigated further.65  
Although the clinical utility of GDA and RDC has been dismissed, the natural products 
have been instrumental in delineating selectivity of Hsp90 inhibitors towards malignant cells.  
Studies have shown that Hsp90 inhibitors accumulate in tumor cells and exhibit high differential 
selectivity.17, 66  Recent immunoprecipitation experiments have demonstrated Hsp90 from 
malignant cells to exist in a heteroprotein complex consisting of client proteins and co-
chaperones (1.3, Figure 2); whereas Hsp90 from normal cells was isolated as the uncomplexed 
homodimer (1.1, Figure 2).17  The heteroprotein complex in tumor cells demonstrates ~100-fold 
higher affinity for the semi-synthetic GDA derivative, 17-AAG.  Furthermore, upon incubation 
of the isolated heteroprotein complex with ATP, a significantly higher ATPase activity was 
measured than exhibited by homodimeric Hsp90; thus demonstrating that the heteroprotein 
complex not only exhibits higher affinity for N-terminal inhibitors but also for the natural 
substrate.17  Subsequent studies revealed ATPase activity of the heteroprotein c mplex to be 
inhibited at lower concentrations of inhibitors than observed for homodimeric Hsp90.17  These 
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results justify the differential selectivity manifested by N-terminal Hsp90 inhibitors for 
malignant cells over normal cells and demonstrate a promising therapeutic window.      
I.3 Clinical Candidate Profiles 
 Co-crystal structures of Hsp90 bound to numerous ligands have been solved, which has 
led to structure-based ligand design efforts.  These efforts have largely aimed at developing 
inhibitors for cytosolic Hsp90, as Hsp90α and Hsp90β have proven more prone to co-
crystallization.  As a result, small molecule inhibitors of Hsp90 are evaluated for inhibitory 
activity against the cytosolic forms of Hsp90; however, the results also suggest pan-inhibition 
against all Hsp90 isoforms.61  At present no research group has been successful towards the 
rational design of isoform selective inhibitors.  
I.3.1 Ansamycin-derived Inhibitors 
 Despite promising anti-tumor activity both in vitro and in vivo, clinical evaluation of 
GDA was halted due to metabolic instability, poor solubility and unfavorable toxicity profiles at 
therapeutically relevant doses.  Furthermore, GDA is a P-glycoprotein (P-gp) substrate and is 
often effluxed from cells prior to eliciting its biological action.67  Upregulation of P-gp pumps is 
recognized as a mechanism for drug resistance in transformed cells.  Consequently, analogs 
based on the benzoquinone ansamycin scaffold have been pursued with the objective of 
improving physicochemical and pharmacological properties amenable to clinical use.   
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Optimization of the ansamycin 
scaffold has centered on the 17-position, 
as substitution at this position results in 
maintained or improved biological activity 
and superior physicochemical 
properties.68, 69  The improved metabolic 
profile of these 17-amino substituted 
analogs is attributed, in part, to the 
enhanced electron-donating ability of the 
amino group, thus attenuating the electrophilicity of the quinone ring.60, 61, 68  Furthermore, 
research has shown the 17-position to project towards the solvent upon Hsp90 binding, which 
allows for the incorporation of solubilizing appendages without affecting Hsp90 affinity.70, 71   
The ansamycin-based analogs under clinical evaluation (Figure 5) include 17-allylamino-17-
demethoxygeldanamycin (17-AAG, tanespimycin, NSC330507, KOS953, CNF1010), 17-
dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG, alvespimycin, KOS1022), 
and the hydroquinone hydrochloride salt of 17-AAG (17-AAGH2, retaspimycin hydrochloride, 
IPI-504).60, 61 
 The first ansamycin-derived analog to enter clinical trials wa  17-AAG, which entered 
evaluation in 1999.  17-AAG exhibits antitumor activity in Her2-positive metastatic breast 
cancer; however, current clinical trials of 17-AAG are aimed at treating myelomas and 
lymphomas.60, 61  Phase I and II clinical trials have been completed with 17-AAG using twice 
weekly and daily dosing schedules.  Preliminary results were promising, however, a lack of 
clinical efficacy for 17-AAG in various phase II trials has dampened enthusiasm.  Dose-
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Figure 5.  Ansamycin-based Hsp90 inhibitors 
under clinical evaluation. 
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dependent hepatotoxicity and inadequate solubility have precluded the approval of 17-AAG.60, 61  
Therefore, numerous strategies have been pursued to increase bioavailability.   
 Evaluation of 17-AAG has demonstrated the compound is reduced by NAD(P)H:quinone 
oxidoreductase (NQO1), resulting in the hydroquinone metabolite 17-AAGH2.
72, 73  Results from 
our laboratory74 and others have shown that the hydroquinone ansamycin-based analogs exhibit 
superior binding affinity versus the quinone counterpart for Hsp90, as well as a slow koff rate.
75, 
76  Dependence of Hsp90 inhibitors upon NQO1 poses numerous liabilities, as NQO1 
polymorphisms are common and NQO1 expression is a known mechanism for drug resistance.77, 
78 Thus, considering the metabolic fate of 17-AAG, resistance acquisition through NQO1 
expression, and the superior affinity of hydroquinone analogs, researchers at Infinity 
Pharmaceuticals developed the hydroquinone hydrochloride salt, 17-AAGH2 (IPI-504).  
Development of this analog eliminated dependence upon NQO1, therefore mitigating metabolic 
liabilities.  Properties of this analog include high solubility in aqueous formulations, and 
improved Hsp90 inhibitory and tumor cell toxicity profiles when compared to 17-AAG.60, 61  
Although 17-AAGH2 is still undergoing phase I/II clinical evaluation, one trial terminated 
prematurely citing “a higher than anticipated mortality rate among patients enrolled in the 
treatment arm.”  Current clinical evaluation is ongoing and 17-AAGH2 is being evaluated for the 
treatment of non-small cell lung cancer (NSCLC), melanomas, and solid tumors as well as in 
combination therapy with the proteasome inhibitor, bortezomib.60, 61 
In parallel to formulation and mechanistic studies of 17-AAG, 17-DMAG was developed 
by Kosan, and incorporates a solubilizing dimethylamino-ethyl moiety that remains protonated at 
physiological pH.60, 61  An improved physicochemical profile is believed responsible for the 
observed improvement in Hsp90 inhibitory activity and biological affect on numerous cancer cell 
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lines.  Although 17-DMAG exhibits an identical binding mode to other ansamycins, it 
demonstrates superior chemical and metabolic stability, lower toxicity, higher solubility and 
bioavailability than both 17-AAG and GDA.60, 61  17-DMAG is now being evaluated in Phase I 
clinical trials for leukemias and advanced solid tumors.  
  Another ansamycin inhibitor of note is the unsubstituted amino analog, 17-AG, which has 
recently entered phase I evaluation and remains an intriguing lead compound. 17-AG is the 
major metabolite of 17-amino substituted ansamycins and maintains Hsp90 affinity and anti-
cancer activity.60, 61  In summary, ansamycin inhibitors of Hsp90 have advanced the furthest in 
clinical trials.  However, numerous detriments still exist with this class of drugs including 
formulation/scheduling difficulties due to heat shock induction, non-ideal toxicity profiles, and 
synthetic accessibility.  These detriments have resulted in efforts to identify small molecule, 
synthetically accessible Hsp90 inhibitors that exhibit improved properties.   
I.3.2 Benzamide Inhibitors 
Serenex developed an Hsp90-based ATP-affinity 
column to identify new inhibitors.61, 79  Cell lysates were 
loaded onto the column, resulting in the capture of ~2000 
ATP-binding proteins.  Compounds were screened for 
their ability to selectively displace Hsp90 from the ATP-
binding column, resulting in identification of small molecule benzamide inhibitors of Hsp90, 
which were subsequently acquired by Pfizer for development as chemotherapeutic agents.61, 79 
  The first benzamide inhibitor entered clinical trials in 2007.  Althoug the lead 
compound exhibited variable bioavailability due to poor solubility and crystal polymorphisms, 
prodrugs were developed to mitigate such detriments.  An orally bioavailable mesylate prodrug, 
 
Figure 6.  Benzamide inhibitor 
developed by Serenex/Pfizer. 
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SNX-5422 (Figure 6), is currently under phase I clinical evaluation with preliminary studies 
focusing on the determination of the maximum tolerated dose (MTD), safety, and toxicity 
profiles.61  Preclinical evaluation suggests a promising biological profile for this class of Hsp90 
inhibitor and the ability to outperform ansamycin analogs in specific trials.79  However, 
benzamide Hsp90 inhibitors, like ansamycins, continue to exhibit dose-dependent cardio oxicity 
that has been attributed to the cardiac potassium human-ether-a-go-go (hERG) channel.80  
Furthermore, benzamide Hsp90 inhibitors are non-selective and bind Hsp90α, Hsp90β, Grp94 
and TRAP-1.61  The non-selective nature of benzamide inhibitors may be an insurmountable 
feature of this inhibitory class and may preclude FDA approval. 
I.3.3 Purine Inhibitors 
 Utilizing structure-based drug design (SBDD), researchers at Memorial Sloan Kettering 
Institute developed small molecule Hsp90 inhibitors consisting of the adenine ring of ATP and 
an aromatic moiety.61  SBDD studies resulted in a lead compound, PU3,81 which was optimized 
independently by Conforma Therapeutics and later by Biogen Idec following acquisition.  A 
pharmacophore model resulted from their optimization studies, which highlig ts three necessary 
features for the purine class of Hsp90 ATPase disruptors: 1) a necessary NH2–C=N capable of 
binding the purine pocket of Hsp90, which mimics the same functionality in ATP; 2) an attached 
aromatic ring positioned six bonds away from the NH2 group and 3) the presence of a purine 
moiety, which consists of optimally positioned basic nitrogen atoms to provide the requisite 
hydrogen bonding interactions.61  Purine based analogs became the first fully synthetic Hsp90 
inhibitors to enter clinical trials in 2005. 
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 Clinical evaluation of purine-based Hsp90 inhibitors has 
resulted in optimism regarding this particular scaffold, as these 
inhibitors exhibit disease-modifying activity against malignancies 
with minimal off-target toxicities.61  Two purine analogs, CNF1010 
and CNF2024 (BIIB021, Figure 7), are currently under evaluation for 
the treatment of hematological and solid tumors.  However, purine 
inhibitors retain detrimental heat shock induction and non-selective isoform binding profiles.60, 61  
Thus, as clinical evaluation progresses, it is hypothesized that similar scheduling difficulties and 
toxicities observed with other N-terminal Hsp90 inhibitors will also be found.  
I.3.4 Resorcinylic Inhibitors  
 Following the lead of numerous other pharmaceutical companies, Vernalis initiated a 
structure-based approach towards the identification of small molecule Hsp90 inhibitors.61, 82  
Eventually, Vernalis and Novartis commenced in collaboration, leading to the identification of 
resorcinylic Hsp90 inhibitors.  This series was optimized and decorat d with solubilizing 
moieties, which produced NVP-AUY922 (Figure 8), and entered clinical 
trials in 2007 as an intravenous infusion.82, 83  Currently, NVP-AUY922 is 
undergoing phase I/II clinical evaluation in combinatorial formulations 
and as a stand-alone agent against a variety of malignancies.60, 61  
    Resorcinylic inhibitors demonstrate minimal selectivity between 
cytosolic Hsp90 and either Grp94 or TRAP-1, ~10-fold and ~60-fold 
respectively.61  However, detriments observed with other inhibitory 
scaffolds continue to plague this class, including heat shock induction and 
off-target toxicities. 
 
 
Figure 7.  Purine 
inhibitor developed 
by Biogen Idec. 
 
Figure 8.  
Resorcinylic 
inhibitor 
developed by 
Novartis. 
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 Another company pursuing resorcinylic inhibitors is Synta Pharmaceuticals.  The exact 
structure for Synta’s lead compound, STA-9090,84 has not been disclosed, however examination 
of the patent literature suggests the scaffold to contain a uniquely functionalized resorcinol.85  
Ongoing clinical evaluation for STA-9090 include phase I/II studies with one study utilizing co-
administration with docetaxel, a microtubule stabilizing agent.61  Published clinical results for 
STA-9090 have been limited; however, discussions with project leaders at the Hsp90 
Symposium in 2010 revealed that similar detriments observed with other classes of Hsp90 
inhibitors are also noted with STA-9090. 
I.3.5 Other Inhibitors 
 The inability to gain FDA approval for any chemotherapeutic, that targets Hsp90, has not 
deterred competitors.  Four other Hsp90 inhibitors have commenced clinical evaluation including 
Kyowa Hakko Kirin’s KW-2478, Myriad Pharmaceuticals’ MPC-3100, Exelixis’ XL888, and 
Astex Therapeutics’ AT13387.60, 61, 85  All of the aforementioned inhibitors are orally available 
except KW-2478, which is administered intraveneously.  None of the structures have been 
disclosed and little clinical data has been released.  However, it can be hypothesized that each of 
these inhibitors will also suffer from the detriments manifested by other N-terminal Hsp90 
inhibitors, as none have demonstrated novel profiles in preliminary disclosures.     
I.4 Biological Concerns with Hsp90 Inhibition 
 Other than detriments observed in the clinical evaluation of Hsp90 inhibitors, numerous 
research groups have identified problematic resistance mechanisms ad biological consequences 
relating to Hsp90 inhibition worthy of consideration. 
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I.4.1 Resistance 
The ability of Hsp90 inhibitors to modulate multiple oncogenic pathways h s launched 
many research endeavors to target this chaperone.  As with the development of any class of 
chemotherapeutic agents, resistance is a concern and recent reports have validated the potential 
for acquired and intrinsic resistance to Hsp90 inhibitors.   
Mutations  
As discussed previously, Hsp90 N-terminal inhibitors act through competitive inhibition 
of the ATP-binding site, disrupting the ability of the chaperone complex to bind and hydrolyze 
ATP.  Thus, the catalytic cycle is inhibited, which leads to client protein degradation and 
eventual cell death.  Due to the competitive nature of Hsp90 inhibitors versus ATP, it was 
assumed that target mutation could 
be dismissed as a potential 
mechanism of resistance; as such 
mutations would alter the ability of 
the protein to bind ATP and 
therefore be deleterious to its 
function.  This hypothesis was 
recently challenged through 
studies with Humicola fuscoatra, a 
fungus that produces RDC and 
exhibits resistance through a single 
point mutation (L34I).86  This 
mutation is located within the N-
 
Figure 9.  Comparison of the ligand interactions with 
L34I mutant Hsp90.  Amino acids from the co-crystal 
structures are shown RDC (green), GDA (cyan), and 
ADP (orange).  Water molecules for RDC (red), GDA 
(cyan), and ADP (Yellow) are shown as spheres.86  
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terminal nucleotide binding pocket and causes an increase in the hydration state of the binding 
domain (Figure 9).  This mutation decreases the affinity of H. fuscoatra Hsp90 for RDC, while 
allowing both GDA and ATP to bind normally; however, it has yet to be det rmined whether 
such a mutation can arise with human Hsp90.86   
Other mutations have been reported to allosterically alter the sensitivity of Hsp90 to 
inhibitors (Table 2).  A yeast-based approach has identified a single point mutation in yeast 
Hsp90 (yHsp90; A107N) that can alter its affinity for both RDC and 17-AAG, without 
compromising ATP binding.87  Expression of Hsp90α and Hsp90β with equivalent mutations, 
A121N for Hsp90α and A116N for Hsp90β, as the sole source of Hsp90 in the yeast system 
Table 2.  Reported mutations to Hsp90 orthologs and the associated 
affects. 
 
Ortholog Species Mutation Effect 
yHsp90  S. cerevisiae A107N 
Stabilizes ATP lid closure; Decreases 
efficacy of RDC and 17-AAG; ATP 
binding unaffected 
yHsp90  S. cerevisiae T22I 
Decreases efficacy of 17-AAG; 
Increases ATPase activity through 
Aha1 independent mechanism 
Hsp90α H. sapiens A121N 
Stabilizes ATP lid closure; Decreases 
efficacy of RDC and 17-AAG; ATP 
binding unaffected 
Hsp90α H. sapiens I128T 
Decreases efficacy of RDC and 17-
AAG in vivo; ATP binding unaffected; 
Increases affinity for Aha1 
Hsp90β H. sapiens A116N 
Stabilizes ATP lid closure; Decreases 
efficacy of RDC and 17-AAG; ATP 
binding unaffected; Increases affinity of 
Aha1 
Hsp90β H. sapiens I123T 
Decreases efficacy of RDC and 17-
AAG in vivo; ATP binding unaffected; 
Increases affinity for Aha1 
Hsp90β H. sapiens T31I 
Decreases efficacy of 17-AAG; 
Increases ATPase activity through 
Aha1 independent mechanism 
Hsp90 H. fuscoatra L34I 
Increased hydration state; Decreases 
affinity for RDC; GDA and ATP 
binding unaffected 
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produced identical results.  This alanine substitution favors closure of the ATP-lid over ATP 
stimulating N-terminal dimerization and association with Aha1, which ncreases ATPase 
activity.  This increase in ATPase activity blocks the ability of inhibitors to bind.87, 88  As shown 
in Table 2, this same Aha1 dependent mechanism of resistance has been link d to Hsp90α I128T 
and Hsp90β I123T mutations.  Additionally, an Hsp90β T34I mutation has been identified that 
causes resistance to Hsp90 inhibition, however the mechanism, although allosteric in nature, 
appears to be Aha1 independent.88   Like most chemotherapeutic agents, other mechanisms of 
resistance to Hsp90 inhibitors have been reported including target induction, al eration in drug 
influx or efflux, and expression modification to associated co-factors.89  
Heat Shock Response 
Another mechanism of resistance displayed towards Hsp90 inhibition involves the heat 
shock response (HSR).  Administration of Hsp90 N-terminal inhibitors leads to the release of 
HSF-1, subsequent trimerization of HSF-1, phophorylation and translocation to the nucleus, 
wherein HSF-1 acts as a transcription factor that binds the heat s ock element to induce the 
HSR.  This induction results in the overexpression Hsp90, Hsp70, Hsp40 and Hsp27; all of 
which serve as anti-apoptotic chaperones that serve to protect the ell.90-92  Induction of these 
pro-survival chaperones, especially Hsp90, has resulted in dosing and sche uling conflicts in 
patients.  In addition, various cell lines exhibiting an increase in drug efflux and metabolism 
have been reported to correlate directly with heat shock induction.  Using photoaffinity labels, 
Benchekroun and colleagues demonstrated the ansamycin analogs act as both substrates and 
inhibitors of P-gp pumps, suggesting drug accumulation may be affected.67  Identification of 
Hsp90 inhibitors that fail to activate the HSR and do not interact with P-gp pumps is important to 
the progression of Hsp90 inhibitor development.  Elimination of these attributes will likely aid in 
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the identification of amenable dosing and scheduling for oncology patients.  Alternatively, 
strategies aimed at inhibiting Hsp90 and Hsp70 simultaneously or inhibit g the C-terminal 
putative binding domain may represent promising avenues to mitigate some of the 
aforementioned problems with current inhibitors.93-95  
Aberrant Function of Co-chaperones  
A myriad of partner proteins that interact with the Hsp90 machinery have been reported 
and it is well accepted that these co-chaperones work in collaboration to modulate the catalytic 
cycle.22  Alteration of the expression of these interactors has suggested ye  another mechanism 
for acquired resistance to Hsp90 inhibition (Table 3).  One example is the overexpression of 
p23/Sba1, which is responsible for binding to and stabilizing the Hsp90·ATP complex.96  Upon 
stabilization, hydrolysis is blocked, and consequently the active site of Hsp90 remains occupied, 
eliminating the ability of inhibitors to modulate ATP binding.  Consequently, Cox and Miller 
have demonstrated that overexpression of p23/Sba1 leads to lower responses to N-terminal 
inhibitors.  Furthermore, Forafonov et al. reported that in the absence of p23/Sba1, cells are more 
responsive to Hsp90 inhibition.97  Additional studies have shown that mutants of p23/Sba1 are 
viable; suggesting that p23/Sba1 
interactions with Hsp90 may 
provide the first evolutionary 
mechanism designed to protect 
cells from Hsp90 inhibition.98  In 
total, resistance to Hsp90 
inhibition has been reported to 
arise through numerous 
Table 3.  Hsp90 co-chaperones and the associated affects 
on the ATPase cycle. 
 
Co-chaperone Effect 
HOP/Sti1 
Decreases ATPase activity through partial 
blockade of N-terminal nucleotide binding 
pocket; Decreases efficacy of GDA and RDC 
p23/Sba1 
Binds to Hsp90/ATP complex, inhibiting 
ATPase actitivity; decreases efficacy of GDA 
and RDC 
Aha1 
Increases ATPase actitivity; decreases 
efficacy of GDA and RDC 
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mechanisms, and these mechanisms must be further detailed and continually monitored during 
clinical studies. 
I.4.2 Genetic Polymorphisms 
Apart from acquired resistance to Hsp90 inhibitors, intrinsically expressed genetic 
polymorphisms have also been identified.  Two of these polymorphisms include NQO1 (DT-
diaphorase) and cytochrome P450 3A4 (CYP3A4).77  Although these polymorphisms seem to 
affect only certain ansamycin scaffolds, they deserve attention, as similar problems may arise 
with future Hsp90 inhibitors.77  Numerous polymorphisms of Hsp90 have been identified; 
however these polymorphisms usually result in diminished Hsp90 activity.99, 100  For this reason, 
only genetic polymorphisms of the enzymes responsible for the metabolism of select ansamycin 
analogs are discussed herein. 
Cytochrome P450 3A4 is one of the most active mixed-function oxidase enzymes in the 
human genome.  In fact, CYP3A4/CYP3A5 are responsible for ~36% of xenobiotic metabolism 
and the CYP3A subfamily is the most abundantly expressed CYP in the liver (30%) and intestine 
(70%).101, 102  Research has identified CYP3A4 as one enzyme responsible for the metabolism of 
17-AAG.103  Genetic polymorphisms of CYP3A4 are common, as over 40 single nucleotide 
polymorphisms have been identified in the CYP3A4 gene within the promoter and/or coding 
regions.  The variability in this metabolic enzyme must be monitored during clinical evaluations 
of ansamycin-based inhibitors of Hsp90, as dosing and scheduling protocols may need to be 
changed.  Furthermore, CYP3A4 is known to be inhibited and/or induced by many substrates, 
including currently used chemotherapeutic agents, antibiotics, immunomodulat rs and anti-
depressants, all of which are commonly prescribed to oncology patients.101, 102  Taken together, 
the genetic variability of the enzyme paired with the potential for serious drug-drug interactions 
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suggests the development of small molecule inhibitors that lack interaction with CYP3A4 is 
important to the development of future Hsp90 inhibitors with clinical applications.      
As discussed previously, outside of cytochromes P450 metabolism, research has shown 
the efficacy of 17-AAG to correlate directly with NQO1 gene expression in vitro.73, 76  High 
expression of the NQO1 gene results in high levels of the DT-diaphor se enzyme, believed to be 
responsible for conversion of 17-AAG to a more efficacious hydroquinone, although the 
mechanism by which this occurs remains under investigation.  Preliminary research suggests up 
to a ~32-fold increase in cellular sensitivity to 17-AAG in cells containing high levels of active 
DT-diaphorase.  Intriguingly, this phenomenon was not observed for GDA, sugge ting that this 
mechanism is not applicable to all ansamycin-based Hsp90 inhibitors.  Furthermore, the 
correlation between NQO1 expression and 17-AAG efficacy is not observed in vivo.104  The 
discrepancy between in vitro and in vivo dependence upon NQO1 expression should be 
considered when evaluating quinone containing Hsp90 inhibitors in preliminary biological 
evaluation.  It is reported that 5−20% of the population is homozygous for the NQO1*2 
polymorphism72, 105 (diminished activity) and DT-diaphorase expression in human tumors is 
known to be variable,106-108 suggesting that although dependence of 17-AAG upon NQO1 has yet 
to be noted in vivo, subsequent quinone containing Hsp90 inhibitors should be evaluated for 
metabolic activation in vivo.    
In total, the variability of CYP3A4 and DT-diaphorase polymorphisms suggest the need 
to determine the levels of these enzymes and their effect on efficacy prior to administration of 
Hsp90 inhibitors.  Furthermore, the ability to correlate enzyme effects in vitro and in vivo may 
help predict the efficacy and/or toxicity of inhibitors before administration.  The design of 
inhibitors exhibiting activity independent of cytochromes P450 metabolism and intracellular 
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reductases especially CYP3A4 and DT-diaphorase, respectively, will likely enhance the 
predictability and widespread use of Hsp90 inhibitors.   
I.4.3 Downstream Biological Effects 
 The effect of Hsp90 inhibitors on the cell cycle and the mechanisms by which inhibitors 
induce cytostasis and/or apoptosis is well understood.18, 19, 109  However, recent research has shed 
light on unexpected biological events resulting from Hsp90 inhibition, leading to unanswered 
questions regarding downstream biological effects.  It is well accepted that Hsp90 inhibition 
results in disruption of the Hsp90 protein folding machinery and subsequent cli t protein 
degradation via the ubiquitin-proteasome pathway, culminating in eventual cell death.  However, 
detrimental downstream effects resulting from Hsp90 inhibition have rec ntly surfaced.  For 
example, although previous research suggests intracellular Hsp90 inhibition to be anti-metastatic 
in nature.110 Price and colleagues report that inhibition of Hsp90 with 17-AAG upregulates 
osteoclast formation and augments bone metastasis.111  This is not surprising, as it was 
previously reported that 17-AAG exhibits pronounced effects on gene expr ssion in cancer cells, 
including upregulation of genes responsible for tumor cell survival and/or growth in bone.112  
Considering metastatic tumor growths cause the majority of deaths in cancer patients, and only 
~20% of breast cancer patients survive longer than 5 years after bone metastasis is discovered,111, 
113 it provides an example as to why disease progression mechanisms must be further delineate .   
 Beyond specific disease progression, one must also look at the effects of Hsp90 inhibition 
on other tissues.  Although the “magic bullet” theory introduced by Erlich was intuitive, no such 
compounds have come to fruition.  Non-selective binding and localization to non-diseased 
tissues have and will continue to cause undesired toxicities for chemot rapeutic agents.  
Evidence shows that Hsp90 inhibition significantly alters dendritic cell function by reducing T-
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cell proliferation and decreasing the ability of mature dendritic cells to present antigens.114  
Importantly, the data suggest that the Hsp90-protein-folding machinery is essential to dendritic 
cell function and patients enrolled in Hsp90 inhibitor clinical trials should be carefully monitored 
for immunosupression. 
 Another example of deleterious downstream effects resulting from Hsp90 inhibition is 
the alteration of glomerular filtration, as reported by Ramirez et al..115  Multiple reports have 
established that Hsp90 is responsible for regulating nitric oxide (NO) synthesis, which is 
dependent upon endothelial nitric oxidase synthase (eNOS).116-119  Due to the eNOS regulation 
on glomerular filtration rate, Ramirez and colleagues investigated the effect of acute Hsp90 
inhibition with RDC on the eNOS pathway and glomerular filtration rate.  The study suggests 
that RDC induced Hsp90 inhibition leads to decreases in eNOS phosphorylation, eNOS 
dimer/monomer ratio and in renal blood flow, therefore decreasing glomerular filtration rate, 
which can be associated with hypertension and metabolic syndrome.115  Although eNOS is a 
known Hsp90-dependent client protein and these results are not too surprising, these effects 
should be monitored during clinical evaluation of Hsp90 inhibitors.     
 Needless to say, further studies are necessary to determine the downstream biological 
effects of Hsp90 inhibition in order to anticipate potential complications that may arise in clinical 
trials.  Future studies on the biology of Hsp90 inhibition will help identify potential side-effects 
including immunosuppression, hypertension, liver toxicity, and kidney failure. 
I.5 Concluding Remarks: The Next Generation of Hsp90 Inhibitors 
 Although cancer is generally defined as a malignant growth or tumor caused by 
uncontrolled cellular division, it is well accepted in the medical and scientific community that 
cancer is also an umbrella term encompassing more than 200 diseases.  It has been noted that 
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each cancer exhibits a unique biological profile and distinct mechanism of progression.  While 
the excitement surrounding Hsp90 research stems from the ability of Hsp90 inhibition to 
simultaneously disrupt all six hallmarks of cancer, many questions remain unanswered as to 
which cancer, which combination of therapies, and which patient population will be responsive 
to each Hsp90 inhibitory scaffold. 
 Until the recent advancement of various small molecule Hsp90 inhibitors into clinical 
trials, the majority of clinically relevant Hsp90 inhibitors have been ansamycin analogs.  Efforts 
to improve upon synthetic feasibility, compound solubility, pharmacological profiles and 
physicochemical properties have inspired further small molecule developm nt.  Although all of 
the inhibitors in clinical trials bind and inhibit the ATPase activity of the N-terminal dimerization 
domain, each scaffold exhibits unique downstream effects and phenotypic changes in specific 
cancers.  Reported structures of clinical candidates include ansamycin, benzamide, purine, and 
resorcinylic based scaffolds. 
 Clinical results have shown Hsp90 inhibitory scaffolds to exhibit unique efficacy profiles, 
suggesting specific scaffolds may be beneficial towards certain cancer types or that 
administration of multiple Hsp90 inhibitory scaffolds may act synergistically against malignant 
growths.60, 61, 120  Furthermore, it is apparent that Hsp90 inhibitory scaffolds may prevent the 
ability of malignancies to develop resistance to commonly prescribed chemotherapeutic 
agents,121, 122 suggesting the identification of a combination therapy may represent th  most 
promising strategy to treat patients.  This has been affirmed in the clinic as the efficacy of 
monotherapy with specific Hsp90 inhibitors, especially ansamycin based scaffolds, has been a 
disappointment; however combinatorial therapies have been promising.60, 61, 122    
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 Identification of new Hsp90 inhibitory scaffolds and elucidation of each scaffold’s 
biological profile will allow clinicians to more rapidly predict the proper indication and/or 
combination of therapies for each patient.  Technological advancements now allow clinicians to 
screen for various biological markers and forecast disease progressi n, confirming the beginning 
of the personalized medicine era.   
 Development of new Hsp90 inhibitory scaffolds and further evaluation of current 
scaffolds may also make it possible to identify isoform selectiv  inhibitors.  Identification of 
such inhibitors may prove beneficial in eliminating potentially detrimental effects observed with 
pan-Hsp90 inhibition.  Multiple isoforms of Hsp90 are found in the human genome and inclu e 
Hsp90α (inducible; cytoplasmic), Hsp90β (constitutive; cytoplasmic), Grp94 (endoplasmic 
reticulum) and TRAP1 (mitochondrial).  Each isoform may be responsible for the maturation of 
distinct client proteins.  Thus, the ability to target one isoform selectively may enhance efficacy, 
therapeutic control and further elucidate the physiological role of ach isoform.  To date, little 
data exist suggesting isoform selectivity for any of the clinically relevant Hsp90 inhibitors.  
Identification of isoform selective inhibitors may allow for degradation of specific client 
proteins, which will further enhance selectivity and provide yet another class of Hsp90 
inhibitors, potentially giving rise to a series of tunable chemotherapeutic agents.         
 Although the ability to identify Hsp90 inhibitory scaffolds is becoming trivial, 
understanding the biological responses inherent to each inhibitory class is difficult.  Hsp90 has 
been validated as an anti-cancer target and clinical trials with various inhibitory scaffolds are 
ongoing.  Both academic and pharmaceutical research teams continue to invest resources in 
Hsp90 modulatory projects, however, the bottleneck for development of Hsp90 inhibitors 
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remains focused on patient responses to Hsp90 inhibition and subsequent effects in gene 
expression levels. 
Multiple Hsp90 inhibitory scaffolds have been identified and each scaffold appears to 
exhibit different binding modes and therefore different profiles of efficacy.  Focus has shifted 
from semi-synthetic ansamycin analogs to scaleable small mo ecules exhibiting superior 
physicochemical and pharmacological properties.  The utilization of competitive small molecule 
Hsp90 inhibitors should provide tools that elucidate mechanisms and downstream biological 
effects resulting from the administration of each scaffold.  Through collaborative efforts between 
medicinal chemists, pharmaceutical chemists and pharmacologists, new small molecule Hsp90 
inhibitors will undoubtedly progress towards clinical evaluation.  The continual development of 
novel Hsp90 inhibitory scaffolds paired with strong biological and mechanistic studies will help 
decipher the complicated network associated with Hsp90 inhibition and bringpersonalized 
chemotherapy to the forefront of medicine. 
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Chapter II 
cis-Radamide Analogs: 
Conformationally Constrained Chimeric N-terminal Hsp90 Inhibitors 
 
II.1 Rationale for the Development of cis-Amide Inhibitors  
 The 90 kDa heat shock proteins (Hsp90) are ATP-dependent molecular chaperones that 
are overexpressed in response to cellular stress and necessary for the folding, activation, 
stabilization and/or rematuration of polypeptides.1-4  Two natural products depicted in Figure 10, 
geldanamycin5 (GDA) and radicicol6 
(RDC), bind competitively to the 
Hsp90 N-terminal binding pocket, 
resulting in degradation of Hsp90-
dependent client proteins via the 
ubiquitin-proteasome pathway.7  
Hsp90 clientele play key roles in 
multiple hallmarks of cancer,8 
therefore, inhibition of the Hsp90 
protein folding machinery results in simultaneous disruption of numerous mechanisms of 
oncogenesis.9, 10  Consequently, not only has Hsp90 emerged as a promising anti-cancer target,11 
but GDA and RDC have proven to represent excellent models for which the development of new 
Hsp90 inhibitors can be pursued for drug development and mechanistic investigations.12 
 
 
Figure 10.  Structures of N-terminal Hsp90 
inhibitors.  GDA and RDC are natural product 
inhibitors and RDA is a chimeric inhibitor developed 
in the Blagg laboratory. 
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Although RDC and GDA both bind the Hsp90 N-terminal 
ATP Bergerat-fold with high affinity, their modes of binding and 
inhibitory activities are different.  Radicicol exists in a bent 
conformation whether bound or unbound to Hsp90 (Figure 11) 
and produces a favorable entropy of 8.3 cal/mol upon binding.13  
Not surprisingly, the predisposition of RDC to the bent 
conformation is believed to be a contributing factor towards its 
similar activity in both cellular and recombinant assays.13, 14  Even 
though RDC is the most potent in vitro natural product inhibitor 
of Hsp90 identified to date, its metabolic liabilities and 
physiologic instability preclude RDC’s use therapeutically.  Thiols such as dithiothreitol (DTT) 
inactivate RDC, suggesting physiological inactivation by endogenous antioxidants such as 
glutathione.15   
Numerous analogs of RDC, which address the instability of the electrophilic epoxide and 
α,β,γ,δ-unsaturated ketone moieties, have been prepared and evaluated for Hsp90 inhibitory 
activity.16, 17  Studies by Moulin et al. utilizing molecular dynamics simulations suggested a 
correlation between the conformation of RDC analogs and potency.14  Despite the syntheses of 
various analogs that exhibit greater stability, potency, and retain a bioactive ground-state 
conformation, no RDC-based analogs are currently under clinical evaluation.  In contrast, 
considerable effort has been devoted towards the development of GDA-based semi-synthetics as 
chemotherapeutics.18 
 In contrast to the bent, cis-amide conformation of GDA when bound to Hsp90, both 
solution and crystal structures have demonstrated that this natural product exists in an extended, 
 
Figure 11.  Solid-state 
structure of RDC (gray) 
overlapped with the 
Hsp90 bound 
conformation (cyan).  
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trans-amide conformation in the 
ground state (Figure 12).19  Multiple 
studies have shown that prior to 
binding Hsp90, GDA must undergo 
two conformational changes; the ansa 
ring must rotate over the 
benzoquinone moiety and the amide 
bond must isomerize from trans to 
cis by rotation about C1–N22 and C20–
N22 (Figure 10).
20  The first event is reported to occur spontaneously; however, isomerization of 
the amide bond is suggested to be Hsp90-dependent.20   Accordingly, isothermal titration 
calorimetry (ITC) experiments have shown that GDA exhibits an entropic penalty of −6.4 
cal/mol upon binding Hsp90.21, 22    
As a consequence of these thermodynamic data, Jez and coworkers hypothesized that 
GDA analogs containing a predisposed cis-amide bond will result in ~1000 fold increase in 
Hsp90 affinity through reduction of entropic penalties.23  Such postulations have inspired 
subsequent studies aimed at determining the effect of trans/cis isomerization of the GDA-amide 
moiety.24-26  However, to the best of our knowledge, no analogs had been synthesized that 
exhibited a predisposed cis-amide functionality. 
 Recently, chimeric inhibitors of Hsp90 were disclosed that contained both the quinone 
ring from GDA and the resorcinol moiety of RDC in an attempt to mimic the hydrogen-bonding 
interactions exemplified by the two natural products when bound to the Hsp90 N-terminal 
nucleotide-binding pocket (Figure 13).27  Although this approach produced novel scaffolds for 
 
Figure 12.  Solution structure of GDA (left) and the 
Hsp90 bound structure (right). 
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Hsp90 inhibition, none of the reported 
analogs exhibited conformational 
characteristics observed by the natural 
products when bound to Hsp90.27-29  
Analysis of the seco derivative, 
radamide (RDA), revealed the potential 
to introduce conformational aspects of 
both natural products when bound to Hsp90, specifically a bent conformation and a ground-state 
cis-amide moiety.  Furthermore, of the three classes of chimeric inh bitors developed in our 
laboratory, RDA represented the most synthetically accessible scaffold for which to incorporate 
the desired conformational characteristics.  The compounds developed have been classified as 
cis-RDA analogs. 
II.2 Synthesis of cis-Radamide Analogs 
 Retrosynthetically, we envisioned the 
desired analogs to be obtained via a Horner–
Wadsworth–Emmons (HWE) olefination reaction 
between cyclic phosphonate 1 and homologated 
aldehydes, 2 and 3 (Scheme 1).  Compound 1 was 
proposed to result from tandem 
reduction/intramolecular cyclization of compound 
4, which could be obtained from commercially 
available 4-benzyloxy-3-methoxybenzaldehyde in 
4 steps.  Aldehydes 2 and 3 could be prepared 
 
Figure 13.  Chimeric Hsp90 inhibitors developed 
in the Blagg Laboratory. 
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Scheme 1.  Retrosynthetic analysis for 
the synthesis of cis-amide chimeric 
analogs. 
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directly from 528 and 6, respectively. 
 Commencing with commercially 
available 4-benzyloxy-3-methoxy 
benzaldehyde (7, Scheme 2), phenol 8 was 
formed via a Dakin oxidation.  Treatment 
of 8 with diazophosphonate 9, enlisting a 
rhodium carbenoid mediated O-H insertion, 
resulted in the phenolic ether 10.  
Regioselective nitration of 10 was 
accomplished utilizing mild ammonium 
nitrate and trifluoroacetic anhydride conditions.  Refluxing 4 with tin(II) chloride resulted in not 
only reduction of the nitro group to the corresponding aniline, but also cyclization to give the 
desired key intermediate, 1.  
The protected resorcinylic precursors were prepared by treatment of 5 with lithium 
diisopropylamide at -78°C to generate the 
benzylic anion, which was quenched upon 
addition of dimethylformamide to afford the 
aldehyde product, 2, or with allyl bromide to give 
6 (Scheme 3).  Oxidation of 6 with osmium 
tetroxide gave the corresponding diol, which was 
cleaved in situ with sodium periodate to yield the 
homologated aldehyde, 3.    
With the synthons in hand, the fragments 
 
Scheme 2.  Synthesis of cis-amide cyclic 
phosphonate. 
 
Scheme 3.  Synthesis of homologated 
aldehydes. 
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were joined via a Horner–Wadsworth–Emmons 
olefination reaction and subsequent removal of 
the tert-butyl-dimethylsilyl protecting groups 
with tetrabutylammonium fluoride provided 
compounds 11–14 (Scheme 4). 
 Originally, we were only interested in the 
saturated analogs, but realized the olefinated 
intermediates exhibited higher conformational 
rigidity than the saturated analogs.  Thus, we 
attempted to selectively remove the benzyl ether 
in the presence of the unsaturated amide with 
procedures reported in literature including FeCl3, 
Pd(OAc)2/Et3SiH/Et3N, and NaI/TMSCl.  However, none of these conditions afforded the 
desired products.  Eventually, conditions employing aluminum(III) chloride in anisole effectively 
cleaved the benzyl ether without alteration of the α,β-unsaturated amide to afford compounds 
15–18 (Scheme 4). 
 Standard hydrogenation conditions with palladium on carbon under hydrogen atmosphere 
yielded racemic products 19 and 20, which were subjected to chiral HPLC to afford the 
enantiopure analogs, 21–24 (Scheme 4). 
 
 
 
 
 
Scheme 4.  Fragment coupling and 
deprotection. 
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II.3 Biological Evaluation of cis-
Radamide Analogs 
II.3.1 Anti-proliferation Activity 
Anti-proliferation studies with 
compounds 15–24 were conducted 
against MCF-7 and SKBr3 breast 
cancer cell lines.  As shown in Table 4, 
the E-olefin is more active than the Z-
olefin for both linker lengths and the 
(+)-enantiomer is more active than the 
(−)-enantiomer.  Rationale for the observed results will be provided in section II.4.1. 
II.3.2 Inhibition of Hsp90 ATPase Activity 
To evaluate this series for inhibition of ATPase activity,30 recombinant yeast Hsp90 
(yHsp90) was overexpressed in Escherichia coli and purified.31  The purified protein was 
incubated with ATP in the presence of 15, 17, 21, and 23 following the assay protocol previously 
Table 4.  Anti-proliferative and ATPase activity of 
cis-amide analogs.  IC50 values expressed as µM 
concentrations unless otherwise noted. 
 
Compound MCF-7 SKBr3 ATPase 
15 3.2 ± 0.1 1.8 ± 0.1 2.4 ± 0.1 
16 78.9 ± 11.3 57.1 ± 8.4 − 
17 1.5 ± 0.1 1.2 ± 0.1 1.6 ± 0.0 
18 9.8 ± 1.9 15.9 ± 4.1 − 
19 4.8 ± 1.1 7.3 ± 0.2 − 
20 6.3 ± 0.9 7.8 ± 0.2 − 
21 3.6 ± 0.1 2.1 ± 0.2 1.5 ± 0.1 
22 14.9 ± 0.2 15.4 ± 0.8 − 
23 2.7 ± 0.5 2.1 ± 0.7 1.2 ± 0.0 
24 78.0 ± 4.4 15.4 ± 0.8 − 
Radamide 18.6 ± 0.9 23.7 ± 1.7 5.9 
GDA 9.8 ± 0.1 nM 8.5 ± 1.1 nM 2.5 ± 0.4 
RDC 47.7 ± 2.6 nM 37.5 ± 4.0 nM 0.4 ± 0.0 
IC50 = concentration needed to produce 50% inhibition 
 
 
Figure 14.  Mechanism of coupled ATPase assay.30 
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developed in our laboratory.  As depicted in Figure 14, inorganic phosphate is produced upon 
Hsp90 mediated ATP hydrolysis.  Maltose phosphorylase subsequently mediates the 
phosphorylation of maltose and cleavage of the glycosidic linkage to produce gl ose-1-
phosphate and free glucose.  The free glucose is oxidized by glucose oxidase in the presence of 
molecular oxygen to produce hydrogen peroxide (H2O2) and gluconolactone.  The resulting 
H2O2, is utilized by horseradish peroxidase to reduce Amplex Red, which is present in the assay 
media, to resorufin, which can be measured spectroscopically.  However, in the presence of an 
Hsp90 inhibitor, Hsp90’s ATPase activity is inhibited and inorganic phosphate is not produced, 
thus the catalytic cycle responsible for resorufin production is circumvented.  This provides a 
method to measure inhibition of Hsp90’s inherent ATPase activity through measurement of 
resorufin absorption at 563 nm.   
As shown in Table 4, the ATPase IC50 values correlated to those observed in the anti-
proliferation studies, suggesting equipotency of these analogs for the heteroprotein complex 
present in transformed cells and the purified homodimeric species employed in the ATPase 
assay. 
II.3.3 Western Blot Analyses 
To confirm the anti-proliferative nature of these compounds resulted from Hsp90 
inhibition, representative compounds 17 and 23 were incubated with MCF-7 cells for 24 h and 
Western blot analyses were performed with the cell lysates (Figure 15).  As expected, the 
immunoblots confirmed concentration-dependent degradation of Hsp90-dependent client 
proteins, Her2 and Raf at concentrations reflective of the corresponding anti-proliferative IC50 
values, thus linking cell viability to Hsp90 inhibition.  Western blot analyses also demonstrated 
induction of the heat shock response, as indicated by induction of Hsp70, which is a common 
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downstream affect resulting from N-terminal Hsp90 inhibition.  Actin is not an Hsp90 client 
protein, therefore its concentration is unaffected by the compounds and can be used as a loading 
control. 
II.4 Interaction of cis-Radamide with Hsp90 and Grp94 
II.4.1 Co-crystal Structure of cRDA Bound to Hsp90 
 Preliminary biological studies with cis-RDA analogs confirmed a characteristic Hsp90 
inhibitory profile.  Since the cis-RDA class of chimeric Hsp90 inhibitors represented a new class 
of conformationally constrained N-terminal inhibitors, compound 20 (cRDA) was sent to Dr. 
Daniel Gewirth at the Hauptman–Woodward Medical Research Institute for co-crystallization 
studies.  The racemic compound was chosen solely on the basis of the quantity of material 
needed.  Inspired by the differences between the co-crystal structures for the seco-analog RDA 
with the N-terminal domains of both the yeast homolog of human Hsp90 (yHsp90N) and canine 
Grp94 (dGrp94N),32 the Gewirth laboratory attempted to co-crystallize cRDA with both 
chaperones; however, only a co-crystal structure for cRDA bound to the N-terminus of human 
Hsp90α (hHsp90N) was successful (Figure 16). 
 
Figure 15.  Western blot analyses of compounds 17 (left) and 23 (right).  
Concentrations denoted in µM. 
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As revealed in the next section, the inability to co-crystallize cRDA with Grp94 does not 
suggest lack of binding.  It is well accepted in the Hsp90 structural biology community that 
Grp94 is inherently difficult to co-crystallize.  This isoform is incredibly flexible and adopts 
numerous ligand dependent conformations.  Thus obtaining co-crystal structures of ligands 
bound to Grp94 is arduous and often unsuccessful.  
Nevertheless, comparison of RDA and cRDA with 
yHsp90N and hHsp90N, respectively, provides 
valuable insights. 
 In both RDA and cRDA (unpublished) co-
crystal structures, the resorcinol ring makes a direct 
hydrogen-bonding interaction with the carboxylate 
of the aspartic acid residue (Asp79 in yHsp90) 
required for ATP binding, thus inhibiting the ability 
of ATP to bind (Figure 17).32  This orientation is 
 
Figure 16.    RDA (left, green) bound to yHsp90N and cRDA (right, blue) 
bound to hHsp90N.   
Gly83
Asp79
Ile77
Leu34
Phe124
H2O
H2O
H2O
 
Figure 17.  Resorcinylic hydrogen-
bonding network of RDA (green) and 
cRDA (blue) with yHsp90N labeled 
amino acids. 
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consistent with all of the resorcinylic inhibitors to date.  
Furthermore, the chlorine functionality on both inhibitors 
projects towards a hydrophobic pocket containing 
Phe124, while the methyl ester participates in a water 
mediated hydrogen-bonding network with Asp79 and the 
backbone of Gly83.32 
 The difference in co-crystal structures becomes 
evident when examining the amide portion of both 
inhibitors.  The quinone moiety of RDA projects towards the solvent (Figure 18) and makes 
direct hydrogen-bonding interactions with Lys44 and Lys98.32  Water-mediated contacts 
between Lys44, Glu88, Asn91, Asn92 and Lys98 and the quinone are also observed.  An 
additional water-mediated hydrogen bond network is also observed between the amide-linker 
and Lys98, Gly121 and the Phe124 backbone.32  These hydrogen-bonding networks elicit a 
trans-amide conformation of RDA when bound to the Hsp90 N-terminal ATP-binding pocket, 
further exemplifying the inability of the chimeric seco 
analogs to bind in a manner observed by either natural 
product inhibitor of Hsp90. 
 In contrast to the linear conformation exhibited by 
RDA, cRDA binds the Hsp90 N-terminal ATP-binding 
pocket in a bent conformation indicative of the constraint 
induced via the cis-amide moiety and the appending 
stereocenter (Figure 19).  This binding mode, provides an 
explanation for the differences in anti-proliferative 
 
Figure 18.  Quinone interactions 
of RDA with yHsp90N. 
 
Figure 19.  Quinone mimic 
interactions of cRDA with 
hHsp90N.  
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activity exhibited by +/– enantiomers or E/Z olefins (Table 4), as a specific geometry is 
necessary for binding the Hsp90 N-terminal binding pocket.  This binding or entation results in 
direct hydrogen-bonding contacts between the cRDA phenol and the backbone of Phe138 
(Phe124 in yHsp90) and Asn51 (Asn37 in yHsp90).  An additional water-mediated hydrogen-
bonding network occurs between the amide carbonyl of cRDA and Lys58 (Lys44 in yHsp90).  
No obvious interactions are observed between cRDA and Asp102, Asn 105, Asn106 or Lys112
(Glu88, Asn91, Asn92 and Lys98 in yHsp90); all of which are amino acids that in eract with the 
quinone region of RDA.  Therefore, the binding mode of cRDA provides a unique set of 
interactions with Hsp90 and yields a novel scaffold exploitable for inhibitor design. 
II.4.2 Binding Affinity of cRDA for Hsp90 and Grp94 
 Although Gewirth and colleagues were unable to isolate high quality crystals of cRDA 
bound to Grp94, they were able to determine the binding affinity of cRDA to both full-length 
yHsp90 and dGrp94 through tryptophan fluorescence quenching (TFQ) analysis.  Proteins 
generally exhibit intrinsic fluorescence, which is predominantly derived from tryptophan 
residues.  Research has shown that upon binding N-terminal ligands, Hsp90 undergoes 
conformational changes that results in tryptophan fluorescence quenching.33  Thus, TFQ has 
 
Figure 20.  Tryptophan fluorescence titration for binding of RDA and 
cRDA to full-length yHsp90 and dGrp94.  
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been validated as a method to measure the binding affinity of Hsp90 N-terminal ligands.  The 
binding affinity values for cRDA were determined to be 0.24 ± 0.12 µM for yHsp90 and 0.11 ± 
0.02 µM for dGrp94.  A comparison of these values to the seco-analog RDA values (0.87 ± 0.14 
µM for yHsp90 and 0.52 ± 0.13 µM for dGrp94), shows ~4-fold increase in affinity for both 
Hsp90 isoforms (Figure 20).  These results suggest that both Hsp90 and Grp94 are sensitive to 
ligand conformation, which provides an avenue for the design of isoform selective inhibitors.  
II.5 Concluding Remarks 
    In conclusion, we have designed, synthesized, and provided biological data for  series 
of analogs that not only contain hydrogen bonding moieties exhibited by GDA and RDC, but 
also exhibit the conformational biases adopted by the natural products when bound to Hsp90 via 
inclusion of a bent conformation and a cis-amide moiety.  In accord with Jez and co-workers,23 
introduction of a cis-amide moiety increased Hsp90 inhibitory activity (~10 fold), compared to 
RDA.  As indicated by the biological results, introduction of both the cis-amide and the bent 
conformation to the chimeric inhibitors does not influence activity against purified recombinant 
Hsp90; however, the activity against cancer cells increased ~10-fold with respect to the seco 
derivative, RDA.  These results coincide with the hypotheses posed by multiple groups, who 
suggest a mechanistic difference between the heteroprotein complex and purified recombinant 
Hsp90.  In addition, the data demonstrates the heteroprotein complex is more ensitive to amide 
isomerization and conformational predisposition. 
 Examination of the co-crystal structures of RDA32 and cRDA bound to Hsp90 homologs 
shows different binding modes of the quinone portions.  RDA binds Hsp90 in a linear
conformation resulting in hydrogen bonding interactions with the lid of the Hsp90 N-terminal 
ATP-binding pocket,32 whereas cRDA folds towards an α-helix at the front of the pocket forming 
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a unique set of hydrogen-bonding interactions.  The unique binding mode of cRDA oupled with 
the binding affinity data for this inhibitor with yHsp90 and dGrp94 led us to development of 
selective Grp94 inhibitors. 
II.6 Methods and Experimentals 
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Ethyl 2-(4-(benzyloxy)-3-methoxyphenoxy)-2-(diethoxyphosphoryl)acetate (10):  Rhodium 
(II) acetate (1 mol%) was added to a solution of 8 (2.90 g, 12.61 mmol) and 9 (1.58 g, 6.32 
mmol) dissolved in anhydrous toluene (50 mL) at rt.  The suspension was warmed to 90 °C for 
18 h under argon atmosphere.  The cooled solution was poured over a plug of celite and 
concentrated in vacuo.  Flash chromatography (SiO2, 20% EtOAc in Et2O) gave 10 (2.00 g, 
70%) as a colorless amorphous solid:  1H NMR (CDCl3, 400 MHz) δ 7.45 – 7.31 (m, 5H), 6.77 
(d, J = 8.8, 1H), 6.67 (d, J = 2.9, 1H), 6.31 (dd, J = 2.9, 8.8, 1H), 5.09 (s, 2H), 4.97 (d, J = 18.8, 
1H), 4.36 – 4.26 (m, 6H), 3.88 (s, 3H), 1.39 (t, J = 7.1, 6H), 1.30 (t, J = 7.1, 3H); 13C NMR 
(CDCl3, 100 MHz) δ 166.6, 152.8 (d, J = 13.6), 150.8, 143.7, 137.2, 128.5 (2C), 127.8, 127.4 
(2C), 114.9, 104.5, 102.1, 75.2 (d, J = 157.7), 71.8, 64.1 (d, J = 7.5), 64.0 (d, J = 6.3), 62.2, 55.6, 
16.4 (d, J = 6.3), 16.4 (d, J = 5.0), 14.1; ESI-HRMS m/z 453.1667 (M + H+, C22H29O8P requires 
453.1678).   
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Ethyl 2-(4-(benzyloxy)-5-methoxy-2-nitrophenoxy)-2-(diethoxyphosphoryl)acetate (4):  
Compound 10 (0.96 g, 2.12 mmol) was dissolved in anhydrous THF (22 mL) and cooled to 0 °C 
under an argon atmosphere.  Ammonium nitrate (0.25 g, 3.12 mmol) was added at once and 
trifluoroacetic anhydride (1.76 g, 8.38 mmol) was added dropwise to the stirred suspension.  The 
resulting solution was warmed to 25 °C and stirred 1 h, before saturated aqu ous NaHCO3 (10 
mL) was added.  The resulting biphasic solution was poured into EtOAc (25 mL) and the 
aqueous layer washed with EtOAc (2 x 20 mL).  The combined organic l yers were combined, 
dried with Na2SO4, and concentrated.  Flash chromatography (SiO2, 20% EtOAc in Et2O) gave 5 
(0.95 g, 91%) as a yellow amorphous solid:  1H NMR (400 MHz, CDCl3) δ 7.63 (s, 1H), 7.47 – 
7.33 (m, 5H), 6.75 (s, 1H), 5.15 (s, 2H), 5.10 (d, J = 17.3, 1H), 4.42 – 4.28 (m, 6H), 3.93 (s, 3H), 
1.44 – 1.36 (m, 6H), 1.31 (t, J = 7.1, 3H); 13C NMR (CDCl3, 100 MHz) δ 165.8, 154.9, 147.7 (d, 
J = 12.2), 143.3, 135.7 (2C), 132.5, 128.7 (2C), 128.4, 127.6, 110.9, 102.1, 77.2 (d, J = 155.4), 
71.6, 64.7 (d, J = 6.3), 64.4 (d, J = 7.5), 62.5, 56.5, 16.4 (d, J = 5.0), 16.4 (d, J = 6.3), 14.1; ESI-
HRMS m/z 496.1380 (M – H+, C22H28NO10P requires 496.1373).   
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Diethyl 6-(benzyloxy)-7-methoxy-3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-2-
ylphosphonate (1):  Tin (II) chloride (2.50 g, 13.16 mmol) was added to a solution of 4 (0.97 g, 
1.95 mmol) in absolute ethanol (2.5 mL) and the suspension was refluxed for 1 h before pouring 
into saturated aqueous NaHCO3 (25 mL).   Precipitate was filtered and washed with EtOAc (25 
mL) and H2O (25 mL).  The filtrate was rinsed with EtOAc (3 x 15 mL) and the organic layers 
were combined, dried with Na2SO4, and concentrated.  Recrystallization with EtOAc and 
hexanes gave 6 (0.59 g, 72%) as a white amorphous solid:  1H NMR (400 MHz, CDCl3) δ 8.71 
(s, 1H), 7.46 – 7.30 (m, 5H), 6.65 (s, 1H), 6.43 (s, 1H), 5.02 (s, 2H), 5.00 (d, J = 16.2, 1H), 4.25 
– 4.03 (m, 4H), 3.82 (s, 3H), 1.34 (t, J = 7.1, 3H), 1.24 (t, J = 7.1, 3H); 13C NMR (CDCl3, 100 
MHz) δ 161.7 (d, J = 3.1), 146.5, 143.7, 136.8, 136.4 (d, J = 1.8), 128.6 (2C), 128.0, 127.5 (2C), 
117.9, 103.8, 102.0, 74.1 (d, J = 151.5), 72.0, 63.8 (d, J = 6.3), 63.7 (d, J = 7.5), 56.4, 16.4 (d, J 
= 7.5), 16.3 (d, J = 5.0); ESI-HRMS m/z 420.1207 (M – H+, C20H24NO7P requires 420.1212).    
   
  
 
Methyl 4,6-bis(tert-butyldimethylsilyloxy)-3-chloro-2-(2-oxoethyl)benzoate (2):  A 1.0 M 
solution of lithium diisopropylamide (3.7 mL, 3.71 mmol) was added dropwise to a solution of 5 
(1.50 g, 3.37 mmol) dissolved in anhydrous THF (35 mL) at -78°C.  After stirring 5 min under 
argon atmosphere, DMF (4.93 g, 67.45 mmol) was added at once under the solution level and the 
reaction stirred at -78°C for 10 min.  The resulting solution was poured into saturated aqueous 
NH4Cl (100 mL) previously cooled to 0°C.  This mixture stirred at 0°C for 30 minutes.  The 
product was extracted with EtOAc (50 mL) and the aqueous layer was washed with EtOAc (3 x 
30 mL).  The combined organic layers were washed with saturated aqueous NaCl, dried with 
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Na2SO4, and concentrated.  Flash chromatography (SiO2, 5% EtOAc in hexanes) gave 2 as a 
yellow oil (0.53 g, 34%):  1H NMR (CDCl3, 400 MHz) δ 9.65 (t, J = 1.5, 1H), 6.42 (s, 1H), 3.84 
(s, 3H), 3.83 (d, J = 1.5, 2H), 1.05 (s, 9H), 0.98 (s, 9H), 0.27 (s, 6H), 0.24 (s, 6H); 13C NMR 
(CDCl3, 100 MHz) δ 195.3, 165.1, 151.1, 149.9, 128.7, 119.0, 117.3, 108.3, 49.9, 43.7, 23.2 
(3C), 23.1 (3C), 16.0, 15.7, -6.7 (2C), -6.8 (2C); ESI-HRMS m/z 473.1940 (M + H+, 
C22H37ClO5Si2 requires 473.1946).   
 
 
Methyl 4,6-bis(tert-butyldimethylsilyloxy)-3-chloro-2-(3-oxopropyl)benzoate (3):  Osmium 
tetraoxide (96 µL) and sodium periodate (0.42 g, 1.96 mmol) were added consecutively to a 
solution of 6 (0.32 g, 0.66 mmol) in dioxane : H2O (3 : 1) (10 mL) and the resulting solution 
stirred for 8 h.  The precipitate was filtered and washed with EtOAc (20 mL).  The filtrate was 
washed with H2O (2 x 20 mL) and saturated aqueous NaCl (20 mL).  The organic layer was 
collected, dried with Na2SO4, and concentrated in vacuo.  Flash Chromatography (SiO2, 5% 
EtOAc in hexanes) gave 3 as a colorless oil (0.27g, 84%):  1H NMR (CDCl3, 500 MHz) δ 9.59 
(s, 1H), 6.11 (s, 1H), 3.63 (s, 3H), 2.73 (dd, J = 6.6, 9.3, 2H), 2.56 (dd, J = 6.5, 9.3), 0.81 (s, 9H), 
0.74 (s, 9H), 0.02 (s, 6H), 0.00 (s, 6H); 13C NMR (CDCl3, 126 MHz) δ 201.0, 168.0, 153.1, 
151.6, 137.7, 121.1, 118.4, 109.6, 52.3, 43.4, 25.6 (3C), 25.4 (3C), 24.7, 18.3, 18.0, -4.4 (2C), -
4.4 (2C); ESI-HRMS m/z 487.2104 (M + H+, C23H39ClO5Si2 requires 487.2103).  
  
 62
 
 
(E)-Methyl 2-(2-(6-(benzyloxy)-7-methoxy-3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-2-
ylidene)ethyl)-3-chloro-4,6-dihydroxybenzoate (11):  Sodium hydride (30.0 mg) was added to 
a suspension of 1 (0.26 g, 0.62 mmol) in anhydrous THF (6 mL) at 0 °C.  The solution was 
warmed to 25 °C and stirred for 30 min under argon atmosphere before cooling t  0 °C.  A 0.1M 
solution of 2 (0.35 g, 0.74 mmol) in anhydrous THF was canulated into the reaction mixture.  
The reaction was stirred at 0 °C for 30 min then warmed to 25 °C for 12 h.  
Tetrabutylammonium fluoride (2.5 mL, 2.47 mmol, 0.1 M solution in THF) was added dropwise 
and the reaction mixture stirred for 1 h.  The reaction was quenched with saturated aqueous 
NH4Cl and extracted with EtOAc (20 mL).  The aqueous layer was rinsed with EtOAc (2 x 20 
mL).  The organic layers were combined, washed with saturated aqueous NaCl, dried with 
Na2SO4, and concentrated.  Repeated flash chromatography (SiO2, 30% EtOAc in hexanes) 
afforded the cis and trans (3:1) isomers giving 11 (0.16 g) and 12 (0.05g) in 67% overall yield:  
1H NMR (Acetone, 400 MHz) δ 9.58 (s, 1H), 7.48–7.32 (m, 5H), 6.72 (s, 1H), 6.66 (s, 1H), 6.53 
(s, 1H), 5.55 (t, J = 6.8, 1H), 5.04 (s, 2H), 4.49 (d, J = 6.8, 2H), 3.89 (s, 3H), 3.80 (s, 3H); 13C 
NMR (Acetone, 126 MHZ) δ 171.3, 162.1, 158.6, 158.3, 147.1, 144.7, 142.2, 142.1, 138.4, 
137.4, 129.2 (2C), 128.7, 128.6 (2C), 119.1, 118.9, 115.2, 108.6, 104.1, 103.3, 102.1, 72.5, 56.8, 
52.8, 31.1; ESI-HRMS 510.0938 (M – H+, C26H22ClNO8 requires 510.0956).  
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(Z)-Methyl 2-(2-(6-(benzyloxy)-7-methoxy-3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-2-
ylidene)ethyl)-3-chloro-4,6-dihydroxybenzoate (12):  1H NMR (Acetone, 400 MHz) δ 9.40 (s, 
1H), 7.37–7.17 (m, 5H), 6.73 (s, 1H), 6.61 (s, 1H), 6.42 (s, 1H), 5.78 (t, J = 6.9, 1H), 4.93 (s, 
2H), 3.97 (d, J = 6.9, 2H), 3.78 (s, 3H), 3.73 (s, 3H); 13C NMR (Acetone, 126 MHZ) δ 171.3, 
162.3, 158.8, 156.8, 147.1, 144.9, 143.4, 141.4, 138.4, 136.5, 129.2 (2C), 128.7, 128.6 (2C), 
115.2, 112.4, 108.3, 104.2, 104.1, 103.3, 102.2, 72.4, 56.8, 53.0, 28.9; ESI-HRMS 510.0959 (M 
– H+, C26H22ClNO8 requires 510.0956). 
 
 
 
(E)-Methyl 2-(3-(6-(benzyloxy)-7-methoxy-3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-2-
ylidene)propyl)-3-chloro-4,6-dihydroxybenzoate (13):  Following the procedure to generate 
11 and 12, cyclophosphonate 1 (0.26 g, 0.62 mmol) was reacted with 3 (0.32 g, 0.66 mmol) in 
anhydrous THF (6 mL).  Repeated flash chromatography (SiO2, 30% EtOAc in hexanes) 
afforded the cis and trans (3:1) isomers giving 13 (0.15 g) and 14 (0.05 g) in 70% overall yield:  
1H NMR (Acetone, 400 MHz) δ 9.44 (s, 1H), 7.48–7.29(m, 5H), 6.69 (s, 1H), 6.69 (s, 1H), 6.49 
(s, 1H), 5.72 (t, J = 8.0, 1H), 5.03 (s, 2H), 3.95 (s, 3H), 3.82 (s, 3H), 3.25–3.20 (m, 2H), 3.03–
2.96 (m, 2H); 13C NMR (Acetone, 126 MHZ) δ 171.6, 162.4, 158.6, 158.1, 147.1, 144.6, 143.5, 
142.2, 138.4, 137.4, 129.2 (2C), 128.7, 128.6 (2C), 120.4, 119.2, 114.8, 108.1, 104.1, 103.0, 
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102.1, 72.5, 56.8, 52.8, 32.9, 27.4; ESI-HRMS 524.1115 (M – H+, C27H24ClNO8 requires 
511.1112).   
 
(Z)-Methyl 2-(3-(6-(benzyloxy)-7-methoxy-3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-2-
ylidene)propyl)-3-chloro-4,6-dihydroxybenzoate (14):  1H NMR (Acetone, 400 MHz) δ 9.48 
(s, 1H), 7.50–7.29(m, 5H), 6.76 (s, 1H), 6.72 (s, 1H), 6.50 (s, 1H), 6.03 (t, J = 7.8, 1H), 5.06 (s, 
2H), 3.98 (s, 3H), 3.83 (s, 3H), 3.30–3.20 (m, 2H), 2.63–2.57 (m, 2H); 13C NMR (Acetone, 126 
MHZ) δ 171.5, 158.7, 156.9, 147.0, 144.7, 143.8, 143.3, 138.4, 136.5, 129.2 (2C), 128.7 (2C), 
128.6 (2C), 128.5, 118.7, 114.8, 113.9, 108.1, 104.2, 103.1, 102.1, 72.4, 56.8, 52.9, 32.0, 25.3; 
ESI-HRMS 524.1109 (M – H+, C27H24ClNO8 requires 511.1112). 
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(E)-methyl 3-chloro-4,6-dihydroxy-2-(2-(6-hydroxy-7-methoxy-3-oxo-3,4-dihydro-2H-
benzo[b][1,4]oxazin-2-ylidene)ethyl)benzoate (15):  Aluminum (III) chloride (42.0 mg, 0.31 
mmol) was added to a solution of 11 (40.0 mg, 0.08 mmol) in anhydrous anisole (10 mL) at 0 
°C.  This mixture was stirred at 0 °C and monitored closely by TLC.  Upon complete conversion 
of 11, MeOH (10 mL) was added and stirring continued while warming to 25°C.  Concentration 
of the resulting solution followed by flash chromatography (SiO2, 50% EtOAc in hexanes) gave 
15 as a white amorphous solid (48.0 mg, 83%):  1H NMR (Acetone, 400 MHz) δ 9.58 (s, 1H), 
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6.63 (s, 1H), 6.57 (s, 1H), 6.52 (s, 1H), 5.52 (t, J = 6.8, 1H), 4.48 (d, J = 6.8, 2H), 3.89 (s, 3H), 
3.79 (s, 3H); 13C NMR (Acetone, 126 MHZ) δ 171.2, 162.0, 158.7, 158.5, 144.0, 142.9, 142.3, 
142.1, 136.0, 119.7, 118.6, 115.2, 108.6, 103.3, 103.1, 101.3, 56.8, 52.8, 31.1; ESI-HRMS 
420.0486 (M – H+, C19H16ClNO8 requires 420.0486). 
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(Z)-methyl 3-chloro-4,6-dihydroxy-2-(2-(6-hydroxy-7-methoxy-3-oxo-3,4-dihydro-2H-
benzo[b][1,4]oxazin-2-ylidene)ethyl)benzoate (16):  Compound 12 (22.0 mg, 0.04 mmol) was 
subjected to the conditions used to generate 15.  Flash chromatography (SiO2, 50% EtOAc in 
hexanes) gave 16 as a white amorphous solid (4.0 mg, 24%):  1H NMR (Acetone, 400 MHz) δ 
9.53 (s, 1H), 6.83 (s, 1H), 6.58 (s, 1H), 6.53 (s, 1H), 5.90 (t, J = 6.9, 1H), 4.10 (d, J = 6.9, 2H), 
3.90 (s, 3H), 3.86 (s, 3H); 13C NMR (Acetone, 126 MHZ) δ 171.5, 162.6, 159.9, 157.0, 144.1, 
143.5, 143.1, 141.3, 135.1, 119.3, 115.7, 112.4, 107.4, 103.4, 103.3, 101.4, 56.9, 52.8, 29.0; ESI-
HRMS 420.0496 (M – H+, C19H16ClNO8 requires 420.0486). 
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(E)-methyl 3-chloro-4,6-dihydroxy-2-(3-(6-hydroxy-7-methoxy-3-oxo-3,4-dihydro-2H-
benzo[b][1,4]oxazin-2-ylidene)propyl)benzoate (17):  Compound 13 (70.0 mg, 0.13 mmol) 
was subjected to the conditions used to generate 15.  Flash chromatography (SiO2, 50% EtOAc 
in hexanes) gave 17 as a white amorphous solid (36.0 mg, 62%):  1H NMR (Acetone, 400 MHz) 
δ 9.46 (s, 1H), 6.66 (s, 1H), 6.54 (s, 1H), 6.50 (s, 1H), 5.70 (t, J = 8.0, 1H), 3.95 (s, 3H), 3.82 (s, 
3H), 3.24 – 3.21 (m, 2H), 3.00 (dd, J = 7.9, 15.9, 2H); 13C NMR (Acetone, 126 MHZ) δ 171.6, 
162.4, 158.9, 158.3, 144.0, 143.4, 142.8, 142.4, 136.0, 120.1, 119.7, 115.0, 107.9, 103.0, 103.0, 
101.3, 56.9, 52.8, 33.0, 27.4; ESI-HRMS 434.0645 (M – H+, C20H18ClNO8 requires 434.0643). 
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(Z)-methyl 3-chloro-4,6-dihydroxy-2-(3-(6-hydroxy-7-methoxy-3-oxo-3,4-dihydro-2H-
benzo[b][1,4]oxazin-2-ylidene)propyl)benzoate (18):  Compound 14 (7.0 mg, 0.013 mmol) 
was subjected to the conditions used to generate 15.  Flash chromatography (SiO2, 50% EtOAc 
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in hexanes) gave 18 as a white amorphous solid (3.2 mg, 57%):  1H NMR (Acetone, 400 MHz) δ 
9.37 (s, 1H), 6.59 (s, 1H), 6.43 (s, 1H), 6.37 (s, 1H), 5.88 (t, J = 7.8, 1H), 3.85 (s, 3H), 3.69 (s, 
3H), 3.16 – 3.06 (m, 2H), 2.49 – 2.42 (m, 2H); 13C NMR (Acetone, 126 MHZ) δ 171.5, 162.4, 
158.7, 157.1, 144.0, 144.0, 143.4, 143.0, 135.1, 119.2, 114.8, 113.6, 108.1, 103.2, 103.1, 101.4, 
56.8, 52.9, 32.1, 25.3; ESI-HRMS 434.0635 (M – H+, C20H18ClNO8 requires 434.0643). 
 
   
 
(±) Methyl 3-chloro-4,6-dihydroxy-2-(2-(6-hydroxy-7-methoxy-3-oxo-3,4-dihydro-2H-
benzo[b][1,4]oxazin-2-yl)ethyl)benzoate (19):  Palladium on carbon (10 mol%) was added to a 
stirred solution of mixed isomers 11 and 12 (60.0 mg, 0.12 mmol) in EtOAc (10 mL).  Hydrogen 
was bubbled through the reaction mixture and then the reaction stirred under H2 atmosphere for 
12 h.  The reaction was filtered through a plug of celite and the resulting filtrate was 
concentrated and purified by flash chromatography (SiO2, 30% hexanes in EtOAc) to give 19 as 
an amorphous white solid (42.4 mg, 85%):  1H NMR (Acetone, 400 MHz) δ 9.38 (s, 1H), 6.70 (s, 
1H), 6.55 (s, 1H), 6.49 (s, 1H), 4.59–4.50 (m, 1H), 3.93 (s, 3H), 3.82 (s, 3H), 3.42–3.18 (m, 2H), 
2.18–2.08 (m, 2H); 13C NMR (Acetone, 126 MHZ) δ 171.4, 166.9, 162.3, 158.6, 144.0, 143.3, 
142.8, 136.3, 121.5, 114.8, 108.2, 103.6, 103.4, 103.0, 78.0, 56.9, 52.8, 30.7, 29.1; ESI-HRMS 
424.0783 (M + H+, C19H18ClNO8 requires 424.0799).  Chiral HPLC with 15% EtOAc in hexanes 
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provided the pure enantiomers:  (+)-21:  [α]D +137.1 (c = 0.24, CHCl3); (−)-22:  [α]D -164.9 (c = 
0.24, CHCl3).  
   
 
 
 
(±) Methyl 3-chloro-4,6-dihydroxy-2-(3-(6-hydroxy-7-methoxy-3-oxo-3,4-dihydro-2H-
benzo[b][1,4]oxazin-2-yl)propyl)benzoate (20):  Following the same procedure used to 
generate 19, an E/Z mixture of 13 and 14 (106.9 mg, 0.20 mmol) were introduced to the 
conditions mentioned above.  The resulting filtrate was concentrated and purified by flash 
chromatography (SiO2, 30% hexanes in EtOAc) to give 20 as an amorphous white solid (49.0 
mg, 85%):  1H NMR (Acetone, 400 MHz) δ 9.32 (s, 1H), 6.68 (s, 1H), 6.54 (s, 1H), 6.49 (s, 1H), 
4.47 (dd, J = 4.4, 8.2, 1H), 3.94 (s, 3H), 3.80 (s, 3H), 3.17–3.05 (m, 2H), 2.01–1.91 (m, 2H), 
1.90–1.78 (m, 2H); 13C NMR (Acetone, 126 MHZ) δ 171.6, 167.3, 162.4, 158.7, 144.2, 144.0, 
142.8, 136.3, 121.6, 114.7, 107.9, 103.6, 102.9, 102.9, 77.6, 56.8, 52.8, 32.8, 31.0, 25.9; ESI-
HRMS 438.0969 (M + H+, C20H20ClNO8 requires 438.0956).  Chiral HPLC with 15% EtOAc in 
hexanes provided the pure enantiomers:  (+) [α]D +11.7 (c = 0.115, CHCl3); (−) [α]D -14.7 (c = 
0.115, CHCl3).  
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Anti-proliferation assay:  MCF-7 and SKBr3 cells were maintained in a 1:1 mixture of 
Advanced DMEM/F12 (Gibco) supplemented with non-essential amino acids, L-glutamine (2 
mM), streptomycin (500 µg/mL), penicillin (100 units/mL), and 10% FBS. Cells were grown to 
confluence in a humidified atmosphere (37 °C, 5% CO2), seeded (2000/well, 100 µL) in 96-well 
plates, and allowed to attach overnight. Compound or geldanamycin at varying concentrations in 
DMSO (1% DMSO final concentration) was added, and cells were returned to the incubator for 
72 h.  At 72 h, the number of viable cells was determined using an MTS/PMS cell proliferation 
kit (Promega) per the manufacturer’s instructions. Cells incubated in 1% DMSO were used as 
100% proliferation, and values were adjusted accordingly. IC50 values were calculated from 
separate experiments performed in triplicate using GraphPad Prism. 
 
ATPase assay:  Recombinant yHsp90 was overexpressed and purified.30, 31  The assay was run 
using optimized conditions previously reported and the PiP r™ Phosphate Assay Kit (Molecular 
Probes #P-22061).  Proper dilutions were made using the provided manufacturer’s instructions.  
Assay solutions and conditions were taken directly from the optimized conditions previously 
published.30  Each well contained a final volume of 100 µL.  Wells were mixed by pipette and 
then shaken for approximately 30 s.  Plates were then covered and incubated at 42 ºC while 
shaken for 2 h.  Absorbance was measured at 563 nm and IC50 values were calculated using 
GraphPad Prism.    Each compound was tested in triplicate on three separate occasions.       
 
Western blot analysis:  MCF-7 cells were cultured as described previously28 and treated with 
various concentrations of drug, GDA in DMSO (1% DMSO final concentration), or vehicle 
(DMSO) for 24 h.  Cells were harvested in cold PBS and lysed in RIPA lysis buffer containing 1 
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mM PMSF, 2 mM sodium orthovanadate, and protease inhibitors on ice for 1 h.  Lysates were 
clarified at 1400 g for 10 min at 4 ºC.  Protein concentrations were d termined by using the 
Pierce BCA assay kit per the manufacturer’s instructions.  Equal amounts of protein (20 µg) 
were electrophoresed under reducing conditions, transferred to a nitrocellulose membrane, and 
immunoblotted with the corresponding specific antibodies.  Membranes wer  incubated with an 
appropriate horseradish peroxidase-labeled secondary anti-body, developed with 
chemiluminescent substrate, and visualized. 
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Chapter III 
 
Design and Synthesis of Proposed 
Grp94 Selective Inhibitors 
 
III.1 Introduction to Grp94 
 The complexity, localization, and uniqueness of each protein dictates the need for 
multiple chaperone systems.1  Furthermore, each cellular organelle maintains unique roles and 
must regulate its own proteostasis.  Thus, the endoplasmic reticulum (ER) contains its own 
chaperoning network required for the development and trafficking of secretory and membrane 
bound proteins.2  As such, the ER contains a resident member of the Hsp90 family, glucose-
regulated protein 94 kDa (Grp94).3, 4  Grp94 was first identified in 1977, upon observation that 
glucose depletion of Rous sarcoma virus transformed chick embryo fibroblasts resulted in the 
over expression of a ~94 kDa protein, which was subsequently named Grp94.5  Research groups 
have since shown that Grp94 exhibits activities unrelated to glucose levels, resu ting in numerous 
aliases including gp96, endoplasmin, Tra-1, or Hsp108.6 
 Similar to other Hsp90 isoforms, Grp94 is ubiquitously expressed in humans.  As shown 
in Figure 21, secretory tissues maintain an especially high level of Grp94 expression.7  As 
expected, introduction of stress to the ER results in the induction of the resident heat shock 
response, the unfolded-protein response (UPR).8  Similar to the cytosol’s ubiquitin-proteasome 
pathway, the ER maintains a protein degradation mechanism, referred to as endoplasmic 
reticulum-associated protein degradation (ERAD).9, 10  Although Grp94 induction is a well 
accepted hallmark of ER stress, the functional role of Grp94 is poorly understood, with the only 
well-studied role for Grp94 being related to immunity.8, 11-13  Interestingly, inhibition of other 
proteins involved in ER proteostasis results in a global induction of the cellular heat shock 
response; however, Grp94 silencing fails to induce either the UPR or the cytosolic HSR.14, 15  
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The function of Grp94 is becoming 
less enigmatic, as its significance in 
cellular homeostasis and disease 
progression has recently attracted the 
attention of numerous researchers. 
III.2 Structure  
As mentioned in Chapter I, 
Grp94 exists as a soluble, obligate 
homodimer; comprised of an N-
terminal domain (NTD), charged-
linker (CL), middle domain (MD), and 
a C-terminal dimerization domain 
(CTD).6, 16-19  Although the NTD 
possesses the characteristic Bergerat-
fold ATP-binding pocket, interactions 
between both the NTD and MD 
cooperate to provide the requisite 
ATP-hydrolysis activity.20, 21  
Residence in the ER is maintained 
through a C-terminal tetrapeptide 
KDEL sequence, which is recognized 
by the KDEL retrieval receptor for 
sequestration.22  The structure of the full-length canine ortholog of Grp94 has been solved in 
 
Figure 21.  Grp94 expression profile in H. sapiens.7 
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addition to various Grp94 truncates with N-terminal ligands.6, 16-19, 23  However, the sites of 
interaction of both co-chaperones and partner proteins for Grp94 remain unknown.      
 Most noteably, Grp94 exhibits a 5-amino acid insertion (QEDGQ) at residues 182–186, 
which is not present in other Hsp90 isoforms (Figure 22).6  This insertion causes a dramatic 
effect on the secondary and tertiary organization of Grp94, especially within the N-terminal 
binding pocket.  As a consequence, the architecture of the binding pocket is unique. Therefore, it 
is not surprising that mechanistic and regulatory disparities between Hsp90 and Grp94 have been 
reported for specific ligands.6, 16, 17, 19, 23 
III.3 Cellular Functions of Grp94 
 Research that ablates Grp94 levels has indicated the chaperone to be essential for the 
development of plants,24 nematodes,14 fruit flies,25 and mice.15  However, its function is non-
essential to the growth of mammalian cell cultures, as Grp94 siRNA experiments demonstrate 
cell lines to grow normally and maintain the ability to differentiate.11, 14  Furthermore, Grp94 is 
essential only to metazoans, as it is not expressed in unicellular organisms, with the exception of 
Leishmania.21  Recent literature has revealed numerous intracellular proteins that are dependent 
upon Grp94 for proper maturation and biological activity.8  Whereas cytosolic Hsp90 maintains 
roles in cell-cycle regulation and signaling, Grp94 mediates cell-to-cell communication through 
the chaperoning of secretory and membrane proteins.  Thus, therapies that target Grp94 may 
represent promising chemotherapeutics for the treatment of pathological conditions that rely 
upon intercellular communication networks.8, 12, 26-28 
 
Figure 22.  Primary sequence alignment of canine Grp94 and hHsp90α depicting the 5-amino 
acid insertion at residues 182–186.6 
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 As shown in Figure 23, Grp94 is responsible for a variety of proteins implicated in cancer 
(IRS-1, IGF-I, IGF-II, integrins) and in immunological conditions (TLRs, integrins, IFN-γ).8  
Most intriguing about the list of clients is the selectivity with which Grp94 operates, even within 
families of proteins, such as TLRs and integrins.  This suggests that the ability to target Grp94 
may result in disease modification with a lower side-effect profile, as fewer clients appear to be 
dependent upon Grp94 than Hsp90.  Therefore, Grp94 isoform selective inhibitors repre ent 
novel biological tools and potential chemotherapies for diseases. 
III.4 Known Ligands: Non-Selective and Selective 
 Amino acids 35-274 of Grp94 exhibit high homology to fragments 9-236 and 1-220 of 
human cytosolic Hsp90 and yeast Hsp90 (yHsp90), respectively.  This domain comprises the N-
 
Figure 23.  Known Grp94 client proteins and method of determination.8 
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terminal nucleotide binding pocket and mediates the binding of structurally unrelated 
compounds, including ATP, GDA, and RDC.  Co-crystallization has shown all three natural 
products bind to the same Bergarat-type ATP-binding pocket, which is comprised of α-helices 
positioned around a platform of β-sheets.6, 17, 18, 23  Grp94 exhibits complete conservation of the 
requisite amino acids responsible for ligand binding to this pocket.  While the inherent ATPase 
activity and conformational equilibrium is comparable for Grp94 and other Hsp90 isoforms,20, 21 
the regulation of conformational reorganization seems mechanistically unique and ligand 
specific.   
III.4.1 Endogenous Ligand: ATP 
Similar to all other members of the GHKL family of ATP bindig proteins, Grp94 binds 
ATP in a unique bent conformation.17  However, Grp94 exhibits a weak binding affinity for 
ATP, which is ~100-fold lower than that observed for cytosolic Hsp90.16, 17  In addition, unlike 
other Hsp90s which bind ADP ~5–10-fold tighter than ATP, Grp94 binds both ATP and ADP 
with similar affinities (Kd ≈ 5µM).
16-18  With the exception of lid reorganization (discussed 
below), the structures of Grp94 in complex with 
nucleotides closely resemble the structures of Grp94 
bound to N-terminal inhibitors.  
Rationale for Grp94’s weak affinity for nucleotides 
is two-fold.  Firstly, the 5-amino acid insertion in Grp94’s 
primary sequence results in a sterically unfavorable 
orientation of Gly196 (Gly121 in Hsp90), which 
diminishes ATP affinity (Figure 24).6  Thus, Grp94 must 
undergo a large conformational reorganization, which 
 
Figure 24.  Depiction of the 
steric clash between Grp94 
Gly196 and the phosphate 
region of ADP.6 
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includes a ~30˚ outward rotation of helices 1-4-5 into an open conformation in order to 
accommodate ATP (Figure 25).17  Secondly, examination of the electrostatics of the Grp94 
ligand binding pocket revealed an acidic and negative surface potential in the phosphate binding 
region, resulting in electrostatic repulsion between the negatively charged phosphates of the 
nucleotide and the protein (Figure 26).23  This is in contrast to the phosphate binding region in 
yHsp90, in which basic groups compliment the phosphate charges.  Thus, electrostatic repulsion 
between Grp94 and nucleotides may further facilitate the rotation of helices 1-4-5, providing the 
requisite energy for conformational reorientation.23  Therefore, the extensive remodeling of 
helices 1-4-5 due to electrostatic repulsion and rotation appear to relieve congestion and may be 
responsible for the low affinity of Grp94 for ATP.  Furthermore, research has shown both of 
these attributes are necessary to result in an open conformation, as delineated in the discussion of 
GDA in section III.4.2.    
H1
H1
H5
H4
H5
H4
 
Figure 25.  Co-crystal structure comparison of ADP bound to yHsp90N (left) and dGrp94N 
(right).  Helices 1-4-5 are labeled and depicted in magenta (Hsp90) and yellow(Grp94). 
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Upon binding ATP, the open conformation of the N-terminal “lid” (helices 1-4-5) of 
Grp94 results in exposure of hydrophobic regions necessary for N-terminal dimerization.17  This 
is in contrast to other Hsp90 isoforms, which undergo lid closure upon binding ATP prior to 
dimerization (Figure 25).29  Therefore, the mechanistic regulation of N-terminal dimerization 
represents a key difference between Grp94 and Hsp90.18 
The aforementioned observations suggest Grp94 to be more sensitive to N-terminal 
ligand structure, but capable of reorganizing to accommodate various functionalities.  Although 
the affinity of Grp94 for ATP is low, the ATPase activity is on par with Hsp90β.21  The amount 
of reorganization exhibited by Grp94 has not been observed in other Hsp90 isoforms, which 
provides a mechanistic anomaly that may be exploitable in the design of isoform selective 
inhibitors. 
III.4.2 Geldanamycin 
 Geldanamycin was originally identified in 199430 as an inhibitor of cytosolic Hsp90 and 
co-crystal structures of GDA·yHsp90 were reported shortly thereafter in 1999.31  As a result of 
these seminal publications, much has been learned about the Hsp90 family, including the 
 
Figure 26.  Co-crystal structure comparison depicting the nature of the phosphate binding 
region between yHsp90N (left) and dGrp94N (right).23 
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existence of four isoforms in the human genome.32  These disclosures and subsequent studies 
revealed GDA to be a pan-inhibitor of all four Hsp90 paralogs, albeit with varying affinities.  
Neckers and colleagues uncovered GDA’s inhibitory activity of Grp94 in 1996.33  Subsequently, 
through competition binding studies, Neckers t al. demonstrated GDA to bind Grp94 (~1 µM) 
with a lower efficiency than Hsp90α or Hsp90β (170 nM);34 however, rationale for the observed 
selectivity was lacking.  The GDA·Grp94 co-crystal structure was not available until 2009, in 
which a collaborative publication between the Gewirth laboratory at Hauptman-Woodward 
Medical Research Institute and our laboratory disclosed the structure.23  This structure has been 
critical to understanding the mechanistic regulation of Grp94 by GDA. 
 Once again, Gly196 plays a critical role in ligand binding and mayexplain the lower 
affinity of GDA for Grp94.  Prior to co-
crystallization, GDA was modeled into the N-
terminal ATP-binding pocket of apo-Grp94.  
These modeling studies revealed a steric clash 
between the macrocyclic amide of GDA and 
the backbone carbonyl oxygen of Gly196 in 
Grp94 (Figure 27).23  Although this clash is 
similar to the predicted ATP clash, the co-
crystal structure between dGrp94N and GDA 
reveals only moderate rearrangement of the flexible “lid” (Figure 28).  Rationale for such a small 
perturbation of the lid can be proposed upon analysis of the electrostatic surfa e of the binding 
pocket.23  Although GDA exhibits a polar quinone ring that binds in the phosphate binding 
region, it is considerably less polar than the phosphate moiety of bound nucleotides.  Thus, the 
 
Figure 27.  Depiction of the Gly196/GDA 
clash observed upon docking GDA into 
apo-Grp94.23 
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lack of electrostatic repulsion allows for 
helices 1-4-5 to remain in a more compact 
conformation than that observed in the 
ADP·dGrp94N complex (Figure 25).  
Cytosolic Hsp90 can accommodate GDA 
through minor structural adjustments and 
the GDA·yHsp90 co-crystal structure is 
similar to that of ATP·yHsp90. 
 Similar to Hsp90, Grp94 binds 
GDA in a bent cis-amide conformation with 
the benzoquinone parallel to the ansamycin 
ring.  Inspection of the remaining GDA and Grp94 interactions reveal similar networks as those 
observed with Hsp90, including direct water-mediated contacts between the carbamate group and 
Asp149; direct hydrogen bonds to Asp110, Lys114, Gly196, 
Gly198, and Phe 199; water mediated interactions between Leu104, 
Asn107, and Thr254; and multiple hydrophobic contacts between 
GDA and Met154, Leu163, Val197, and Phe199.23 Considering the 
binding affinity data and co-crystal structure evidence, it is not 
surprising that GDA-derived analogs can be utilized to design 
isoform selective inhibitors.  In fact, GDA-derived WX514 (Figure 
29) exhibits a ~90-fold higher binding affinity for Hsp90 than 
Grp94.34  However, the rationale for cytosolic selectivity exhibited by analogs of this class 
remains undisclosed.  
H1
H4
H5
Figure 28.  Co-crystal structure of GDA with 
dGrp94N.  The mobile subdomain consisting of 
helices 1-4-5 is depicted in cyan. 
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Figure 29.  Structure 
of WX514, a selective 
inhibitor of cytosolic 
Hsp90. 
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III.4.3 Isoform Selective Inhibitor: N-ethylcarboxamidoadenosine      
 Studies regarding the adenosine receptors A1 and A2 in the 1980s resulted in significant 
knowledge pertinent towards understanding the adenosine receptor.35, 36  However, upon 
identification of the adenosine A2 receptor, a second class of proteins containing an adenosine 
A2-like binding site was identified.
37  Subsequent studies revealed 
Grp94 to be a major contributor in adenosine A2 ligand binding, 
exhibiting a binding affinity of ~200 nM for 5’-N-
ethylcarboxamidoadenosine (NECA), a broad spectrum adenosine A2 
receptor agonist (Figure 30).38  In fact, Grp94 was eventually 
identified as the prominent cellular target of NECA.38  Furthermore, 
NECA was shown to exhibit no apparent binding affinity for Hsp90,16 establishing NECA as the 
only known Grp94 selective inhibitor. 
 In order to provide rationale for NECA’s Grp94 binding selectivity, Gewirth and 
colleagues solved the NECA·dGrp94N and the RDC·dGrp94N co-crystal structures.6  These 
structures provided a direct comparison between the Grp94 selective inhibitor, NECA, and a 
potent pan-Hsp90 inhibitor, RDC.  Prior to solution of the co-crystal structures, it was unknown 
what role the 5-amino acid insertion in Grp94’s primary sequence provided.  
 Analyses of the co-crystal structures, suggest a unique binding domain for Grp94, which 
is lacking in the RDC·yHsp90 structure, that interacts with the 5’-ethyl moiety of NECA.6  As 
expected, the adenine moiety of NECA exhibits identical interactions to Grp94 as observed in 
ATP/ADP·Hsp90 complexes.  This can be explained due to the complete conservation of 
requisite amino acids known to interact with nucleotides via direct and water-mediated 
hydrogen-bonding networks.  The second domain that interacts with NECA is a unique structural 
N
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Figure 30.  Structure 
of NECA. 
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feature specific to Grp94, which is introduced by the 5-amino acid insertion in its primary 
sequence.  The insertion occurs in the helix 1-4-5 subdomain and results in lengthening of helix 
4 and two structural modifications.6  Firstly, the orientations of Ala167 and Lys168 (Ala97 and 
Lys98 in Hsp90) are reorganized, which results in a volumetric increase of the second binding 
domain.  This increase in volume can accommodate the 5’-ethyl moiety pr sent in NECA.  
Secondly, the lengthening of helix-4 produces increased flexibility and a conformational re-
orientation of helices 1-4-5, which may facilitate ligand binding.6  As observed in Figure 31, 
NECA provides a direct hydrogen-bond with the backbone carbonyl of Asn162 in dGrp94 and 
the 5’-ethyl moiety is stabilized through van der Waals 
interactions with Val197 and Tyr200.  This pocket is 
not present in yHsp90, and consequently it is not 
surprising that this type of “conformational switch” 
had not been previously observed in other Hsp90 
isoforms.  Furthermore, this pocket is present in apo-
Grp94, suggesting that it is not ligand-induced, but 
rather inherent in nature. 
 Rationale for the inability of NECA to bind 
Hsp90 can be postulated through molecular modeling studies.  Since the adenine portion of 
NECA, ATP, and ADP bind to Grp94 and Hsp90 with identical interactions, positioning of the 
5’-ethyl moiety of NECA is dictated by the adenine orientation.  Thus, upon modeling NECA 
into yHsp90’s N-terminal binding pocket, a clash between the 5’-ethyl group and the main chain 
carbonyl oxygen of yHsp90 Gly121 (Gly196 in Grp94) occurs.6  The repercussions of protein 
remodeling to accommodate the ligand are detrimental, as remodeling of the protein would result 
Figure 31.  Interaction of NECA 
within the second binding domain 
unique to Grp94. 
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in net energy expenditure.  Therefore, it can be hypothesized that the 5’-ethyl group of NECA is 
the sole factor responsible for the selective binding of NECA to Grp94. 
 Interestingly, these results suggest that the position of Gly196 in Grp94 maintains a 
discriminatory role towards ligand binding, as its orientation precludes the binding of 
endogenous nucleotides, but allows for the binding of NECA.  This is in contrast to yHsp90, as 
the respective Gly121 allows binding of ATP/ADP, but prevents NECA binding.  In total, the 
observations for ligand specificity and regulation provide evidence that Grp94 selective 
inhibitors can be designed; however, analogs based on the NECA scaffold have proved 
unsuccessful thus far.    
III.5 Proposal of Grp94 Selective Inhibitors 
 As mentioned previously, the chimeric inhibitor radamide (RDA) was co-crystallized 
with both yHsp90N and dGrp94N.23  Analysis of the two co-crystal structures revealed the 
resorcinol to bind similarly to both isoforms.  However, the quinone moiety of RDA binds 
yHsp90 in a linear, trans-amide conformation; while upon binding Grp94, two unique bent 
conformations that project the quinone into the hydrophobic NECA 5’-binding pocket are 
observed (50% occupancy each).  One conformation manifests a cis-amide orientation, while the 
second, orthogonal conformation contains a trans-amide (Figure 32).  The quinone moiety of 
RDA exhibits distinct interactions with each protein, which provides a tarting point for the 
rational design of Grp94 selective inhibitors.  In fact, analysis of the RDA·yHsp90 co-crystal 
structure suggests the quinone to be involved in an intricate hydrogen-bonding network, whereas 
it’s interaction with Grp94 is limited.  This has led to speculation that the quinone may be 
dispensable for Grp94 binding, but obligatory for Hsp90 binding.   Considering these 
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observations, two approaches were utilized to design Grp94 selective inh bitors: 1) manipulation 
of the quinone moiety; and 2) conformational constraint to incorporate a cis-amide bioisostere. 
III.5.1 Quinone Substitution 
 The first series of analogs aimed at manipulating the substit tion pattern of the quinone 
ring, and thus eliminating critical interactions required for binding Hsp90, but main aining Grp94 
inhibitory activity.  Furthermore, analyses of the co-crystal ructures suggested a more intricate 
 
Figure 32.  Co-crystal structures of RDA bound to yHsp90 (left) and Grp94 (right).  
The two RDA conformations populated when bound to Grp94 are depicted in cyan and 
yellow. 
G
ly
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Figure 33.  Quinone hydrogen bonding network comparison between yHsp90 (left), and the 
cis-amide (middle) and trans-amide (right) conformations of RDA that bind Grp94. 
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hydrogen-bonding network between the quinone and yHsp90 than that which was observed for 
the quinone (in either orientation) and Grp94 (Figure 33).  Therefore, analogs 25–27 were 
proposed to systematically evaluate substituents of the RDA quinone ring. To design these 
analogs, the trans-amide conformation 
exhibited by RDA when bound to Grp94 
was chosen as the design template, as this 
conformation represents the lowest energy 
and highest populated conformation of the 
amide in solution.   
Removal of the 5-carbonyl (25, 
Figure 34) on the RDA quinone would 
eliminate hydrogen-bonding interactions between the carbonyl and Lys98 as observed in the 
yHsp90 structure.  Interactions between Lys98 and the 5-carbonyl were also observed in the 
GDA·yHsp90 complex, which is critical to the binding affinity.  Although this manipulation will 
also change the oxidation state of the 2-carbonyl, this should not affec interactions with Lys44, 
as the hydroquinone of RDA interacts similarly in the yHsp90 N-terminal binding pocket.  
Furthermore, the trans-amide conformation exhibited by RDA when bound to Grp94 suggests no 
apparent function of the 5-carbonyl (Figure 33).  Thus, removal of this functionality should result 
in lower affinity for Hsp90, while unaffecting interactions with Grp94.   
Further reduction of 25 via removal of the 2-oxo functionality provides analog 26, which 
lacks the hydrogen bonding capability with Lys44 and Lys98 of yHsp90.  This manipulation is 
also predicted to affect the hydrogen-bonding network of the ligand with Grp94, as this 
functionality is involved in hydrogen bonding with the backbone amides of Gly196 and Phe199.  
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Figure 34.  Proposed analogs which lack key 
functionalities for Hsp90 binding. 
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However, the NECA·Grp94 co-crystal structure suggests this region of Grp94 to be hydrophobic 
in nature.6  Therefore, this manipulation may still provide beneficial van der Waals and/or π-
stacking interactions with Grp94.  Lastly, removal of the 4-methoxy moiety will provide analog 
27, which eliminates all functionalities present on the RDA quinone.  Development of this 
focused library allows for the rapid evaluation of the des-quinone hypothesis.  
III.5.2 Incorporation of a cis-Amide Bioisostere 
 The second approach towards the design Grp94 selective inhibitors encompasses a 
bioisosteric replacement strategy.  Previous evaluation of cRDA (Chapter II) revealed that 
chimeric analogs exhibiting a conformationally biased cis-amide moiety resulted in an improved 
binding affinity for Grp94.  While the affinity for Hsp90 also improved, the ~110 nM affinity for 
Grp94 and ~5-fold improvement from RDA was most intriguing.  However, th  synthesis of 
cRDA was not amenable to facile SAR development.  Upon evaluation of cis-amide bioisosteric 
replacements, imidazole was chosen for two reasons: 1) aldehyde 3, utilized for the synthesis of 
RDA and cRDA, could be maintained as an advanced intermediate for the synthesis of a variety 
of analogs; and 2) optimized methodology had been previously reported, which enabled the rapid 
preparation of analogs in a straightforward manner with relatively inexpensive reagents.39-41 
 Closer analysis of the second 
Grp94 binding domain revealed the 
pocket to be hydrophobic in nature and 
to contain π-rich amino acids Phe199 
and Tyr200, which are poised for π-
stacking interactions.  In agreement 
with the "dispensable quinone" 
 
Figure 35: Initial 
imidazole analogs 
with varying linker 
length. 
Table 5.  Surflex binding 
scores of 28–32. 
Compound 
Binding 
Score 
28 4.80 
29 5.94 
30 - 
31 - 
32 - 
RDA 3.82 
cRDA 4.71 
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hypothesis, molecular modeling studies with imidazoles containing a pendent benzene ring 
(Figure 35) provided the desired interactions.  Utilizing Surflex docking software,42, 43 analogs 
28–32 were docked to the RDA·Grp94 complex (PDB: 2GFD).  As shown in Table 5, 28 and 29 
were the only analogs that bound successfully to Grp94; and both exhibited bet r binding scores 
than RDA and cRDA.  Furthermore, 28–32 failed to dock to the RDA·yHsp90 complex (PDB: 
2FXS).  Therefore, the first series of analogs synthesized consisted of an imidazole linkage 
flanked with a benzene ring attached with various linker lengths.  Because of the flexible Grp94 
lid region and inability of available modeling programs to consider this, linker lengths n = 3 and 
4 were synthesized to confirm the docking results.  The biological evaluation of these analogs 
will be described in detail in 
Chapter IV; however, analog 29 (n 
= 1) exhibited superior activity in 
the functional Grp94 inhibitory 
assay, which was in agreement with 
modeling studies.  Therefore, 
functionalized analogs based upon 
29 were designed for subsequent 
development. 
 Analogs chosen for 
synthesis are depicted in Figure 36.  
Compounds 33 and 34 were 
designed to evaluate steric 
constraints and stereochemical 
 
Figure 36.  Imidazole analogs based upon 29.
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dependence.  Analogs 35–38 were designed to assess the compatibility and optimal location of 
hydrogen bond acceptors.  The exact binding orientation of the imadazole nalogs remained 
unknown at the onset of analog development, however it was hypothesized that the presence of a 
hydrogen-bond acceptor may interact favorably with Tyr200 or the protein backbone, thus 
increasing affinity for Grp94.  Furthermore, incorporation of a cis-amide bioisostere altered the 
projection angle towards the 5’-binding pocket present in Grp94.  Thus, analogs 35–38 were 
devised to provide an evaluation of all possible locations, as hydrogen bonding is geometrically 
and directionally dependent.  Additionally, analog 39 
was designed to mimic the methyl ether present in 
RDA and cRDA, providing further information on the 
effects of hydrogen-bond donors, and to assess the 
spatial limitations of the binding pocket. 
 In parallel to the development of substituted 
analogs based on 29, alkyl-imidazoles (40–43, Figure 
37) were designed.  These compounds were 
hypothesized to mimic NECA’s 5’-ethyl functionality, 
which interacts with the Grp94 binding domain v a van 
der Waals interactions with Val197 and Tyr200, rather than π-stacking interactions.    
III.6 Synthesis of Proposed Grp94 Selective Inhibitors 
 A key component of selecting the two aforementioned hypotheses for evaluation was the 
ability to utilize advanced intermediates previously reported by our laboratory.  This allowed for 
the rapid evaluation of the two hypotheses in an efficient manner without significant scaffold 
development. 
 
Figure 37.  Alkyl-imidazoles. 
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III.6.1 Synthesis of des-Quinone Analogs 
 Synthetically, analogs 25–27 were obtained in 3-steps from the previously disclosed 
aldehyde, 3 (Scheme 5).44, 45  Commencing with a Pinnick oxidation, acid 4444, 46 was obtained in 
high yield and subsequently coupled with the necessary anilines through employment of 
EDCI/DMAP peptide coupling conditions.  Facile removal of the tert-butyldimethylsilyl (TBS) 
protecting groups with tetra-n-butylammonium fluoride (TBAF) yielded the desired compounds 
25–27.  Biological evaluation of these analogs is discussed in detail in Chapter IV. 
III.6.2 Synthesis of Imidazole Bioisosteric Analogs 
The imidazole linked compounds were obtained in two steps from 3.  As shown in 
Scheme 6, aldehyde 3 was treated with primary amines, glyoxal, and ammonium bicarbonate,39, 
40 followed by subsequent TBS removal with 
TBAF to produce the desired compounds 
(28–43), in acceptable yields.  Biological 
evaluation of these analogs is discussed in 
detail in Chapter IV. 
III.7 Concluding Remarks 
 In conclusion, analysis of RDA·yHsp90N, cRDA·hHsp90N, and RDA·dGrp94N co-
crystal structures revealed ligand specific interactions, which were exploitable for isoform 
 
Scheme 5.  Synthetic route to des-quinone analogs. 
 
Scheme 6.  Synthetic route to analogs 28–43. 
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selective inhibitors.  Each of the 19 analogs designed provided informatin critical for the 
advancement of Grp94 selective inhibitors.  Furthermore, the proposed analogs allow for an 
efficient evaluation of both the des-quinone and the cis-amide bioisostere hypotheses.  Chapter 
IV will discuss the biological assays utilized to evaluate analogs 25–43 for isoform selectivity.  
III.8 Methods and Experimentals 
General procedure for analogs 25–27:  Acid 44 (1 equiv.) was dissolved in anhydrous DCM at 
25 ˚C.  To the reaction flask was added 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide) 
(EDCI, 3 equiv.) followed by 4-dimethylaminopyridine (DMAP, 3 equiv.).  After dissolution, a 
0.5 M solution of the required aniline (3 equiv.) in anhydrous DCM was added to the reaction 
flask.  The reaction was stirred at 25˚ C until complete conversion of the acid was observed by 
TLC.  Upon complete conversion, the reaction mixture was poured into H2O and extracted with 
DCM.  The organic layers were combined, dried with MgSO4 and concentrated in vacuo.  The 
resulting residue was redissolved in wet THF and tetra-n-butylammonium fluoride (TBAF, 4 
equiv.) was added dropwise to the reaction flask at room temperature.  After complete 
conversion of starting material, as observed by TLC, the reaction was quenched with saturated 
aqueous NH4Cl and extracted with EtOAc.  The organic layers were combined, dried with 
Na2SO4, and concentrated in vacuo.  Purification conditions and yields for all compounds are 
described below: 
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methyl 3-chloro-4,6-dihydroxy-2-(3-((2-hydroxy-4-methoxyphenyl)amino)-3-
oxopropyl)benzoate (25):  Purified by flash chromatography utilizing 95:5 (DCM:MeOH) as 
the eluent; Yield: 63 %; 1H NMR (CDCl3, 500 MHz) δ 9.27 (s, 1H), 7.19 (d, J = 8.8 Hz, 1H), 
6.52 (s, 1H), 6.48 (d, J = 2.8 Hz, 1H), 6.41 (dd, J = 8.8 Hz, 2.8 Hz, 1H), 3.96 (s, 3H), 3.75 (s, 
3H), 3.45–3.48 (m, 2H), 2.77–2.80 (m, 2H); 13C NMR (CDCl3, 125 MHz) δ 172.9, 171.4, 162.6, 
159.4, 158.9, 151.1, 142.8, 123.9, 120.9, 115.0, 108.0, 106.3, 104.4, 103.3, 55.6, 53.0, 36.1, 
30.6; ESI-HRMS m/z 394.0684 (M – H, C18H17ClNO7 requires 394.0694). 
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methyl 3-chloro-4,6-dihydroxy-2-(3-((4-methoxyphenyl)amino)-3-oxopropyl)benzoate (26):  
Purified by flash chromatography utilizing 97:3 (DCM:MeOH) as the eluent; Yield: 61 %; 1H 
NMR (Acetone-D6, 500 MHz) δ 10.98 (bs, 1H), 9.02 (s, 1H), 7.59 (d, J = 9.0 Hz, 1H), 6.87 (d, J
= 9.0 Hz, 1H), 6.50 (s, 1H), 3.95 (s, 3H), 3.77 (s, 3H), 3.40–3.43 (m, 2H), 2.62–2.65 (m, 2H); 
13C NMR (Acetone-D6, 125 MHz) δ 171.4, 170.4, 162.4, 158.6, 156.7, 143.3, 133.7, 121.6 (2C), 
114.8, 114.6 (2C), 108.3, 103.1, 55.6, 52.9, 36.7, 29.1; ESI-HRMS m/z 378.0738 (M – H, 
C18H17ClNO6 requires 378.0744). 
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methyl 3-chloro-4,6-dihydroxy-2-(3-oxo-3-(phenylamino)propyl)benzoate (27):  Purified by 
flash chromatography utilizing 90:10 (DCM:MeOH) as the eluent; Yield: 83 %; 1H NMR 
(CDCl3, 500 MHz) δ 11.16 (s, 1H), 7.46 (d, J = 7.9 Hz, 2H), 7.27 (t, J = 7.9 Hz, 2 Hz), 7.10 (s, 
1H), 7.06 (t, J = 7.4 Hz, 1H), 6.53 (s, 1H), 6.05 (bs, 1H), 3.91 (s, 3H), 3.42–3.45 (m, 2H), 2.55–
2.58 (m, 2H); 13C NMR (CDCl3, 125 MHz) δ 170.4, 169.9, 163.0, 156.2, 141.7, 137.8, 129.1 
(2C), 124.4, 119.7 (2C), 113.9, 106.9, 103.0, 52.7, 36.7, 28.8; ESI-HRMS m/z 348.0629 (M – H, 
C17H15ClNO5 requires 348.0639). 
 
General procedure for compounds (28–43):  Aldehyde 3 (1 equiv.) was dissolved in wet 
MeOH at 25˚ C.  The required aniline/amine (1 equiv.) was added dropwise via a syringe to the 
reaction flask followed by addition of ammounim bicarbonate (NH3C 2O3, 1 equiv.).  Glyoxal 
(1 equiv.) was then added dropwise via a syringe and the reaction was allowed to stir at 25 ˚ C 
for 8 h.  Upon complete conversion of the aldehyde, TBAF as observed by TLC, TBAF was 
added dropwise via syringe and the reaction was allowed to stir at 25 ˚C for ~30 min, upon 
which time, the reaction was quenched with sat. aq. NH4Cl and extracted with EtOAc.  The 
organic layers were combined, dried with Na2SO4, and concentrated in vacuo.  All compounds 
were purified via flash chromatography utilizing 95:5 (DCM:MeOH) as the eluent.  Yields for all 
compounds are provided below:   
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methyl 3-chloro-4,6-dihydroxy-2-(2-(1-phenyl-1H-imidazol-2-yl)ethyl)benzoate (28): Yield: 
28%; 1H NMR (CDCl3, 400 MHz) δ 7.56 – 7.39 (m, 3H), 7.32 (d, J = 6.8, 2H), 7.14 (s, 1H), 7.05 
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(d, J = 1.0, 1H), 6.51 (s, 1H), 3.84 (s, 3H), 3.50 – 3.42 (m, 2H), 3.06 – 2.97(m, 2H); 13C NMR 
(CDCl3, 125 MHz) δ 171.0, 162.9, 158.2, 147.7, 141.4, 137.4, 129.6 (2C), 128.7, 127.0, 126.1 
(2C), 121.1, 114.9, 105.7, 102.6, 52.53, 31.15, 26.20; ESI-HRMS m/z 371.0797 (M – H, 
C19H16ClN2O4 requires 371.0799). 
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methyl 2-(2-(1-benzyl-1H-imidazol-2-yl)ethyl)-3-chloro-4,6-dihydroxybenzoate (29): Yield: 
54%; 1H NMR (CDCl3, 400 MHz) δ 11.74 (bs, 1H), 7.37 – 7.29 (m, 3H), 7.09 – 7.07 (m, 3H), 
6.88 (d, J = 1.4, 1H), 6.52 (s, 1H), 5.14 (s, 2H), 3.85 (s, 3H), 3.60 – 3.47 (m, 2H), 3.08 – 2.95(m, 
2H); 13C NMR (CDCl3, 125 MHz) δ 171.0, 162.8, 159.6, 147.8, 141.2, 135.9, 129.1 (2C), 128.2, 
126.7 (2C), 126.1, 120.3, 115.5, 105.0, 102.7, 52.6, 49.7, 30.9, 26.0; ESI-HRMS m/z 385.0953 
(M – H, C20H19ClN2O4 requires 385.0955). 
 
methyl 3-chloro-4,6-dihydroxy-2-(2-(1-phenethyl-1H-imidazol-2-yl)ethyl)benzoate (30): 
Yield: 51%; 1H NMR (CDCl3, 400 MHz) δ 7.35 – 7.22 (m, 3H), 7.07 (d, J = 6.9, 2H), 7.01 (s, 
1H), 6.82 (s, 1H), 6.48 (s, 1H), 4.16 (t, J = 7.1, 2H), 3.90 (s, 3H), 3.53 – 3.40 (m, 2H), 3.04 (t, J
= 7.1, 2H), 2.85 – 2.72 (m, 2H); 13C NMR (CDCl3, 125 MHz) δ 170.8, 162.8, 158.5, 147.3, 
141.4, 137.2, 128.9 (2C), 128.7 (2C), 127.1, 126.4, 119.1, 115.0, 105.6, 102.7, 52.6, 47.4, 37.6, 
30.8, 25.8; ESI-HRMS m/z 399.1115 (M – H, C21H20ClN2O4 requires 399.1112). 
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methyl 3-chloro-4,6-dihydroxy-2-(2-(1-(3-phenylpropyl)-1H-imidazol-2-yl)ethyl)benzoate 
(31): Yield: 48 %; 1H NMR (CDCl3, 400 MHz) δ 7.32 – 7.11 (m, 5H), 7.04 (s, 1H), 6.89 (s, 1H), 
6.51 (s, 1H), 4.02 – 3.81 (m, 5H), 3.63 – 3.44 (m, 2H), 3.06 – 2.91 (m, 2H), 2.68 (t, J = 7.6, 2H), 
2.22– 2.04 (m, 2H); 13C NMR (CDCl3, 125 MHz) δ 170.9, 162.8, 159.3, 147.2, 141.3, 140.2, 
128.7 (2C), 128.3 (2C), 126.4, 126.2, 119.1, 115.4, 105.2, 102.8, 52.6, 45.3, 32.7, 32.2, 30.9, 
25.9; ESI-HRMS m/z 413.1272 (M – H, C22H23ClN2O4 requires 413.1268). 
 
methyl 3-chloro-4,6-dihydroxy-2-(2-(1-(4-phenylbutyl)-1H-imidazol-2-yl)ethyl)benzoate 
(32): Yield: 37 %; 1H NMR (CDCl3, 400 MHz) δ 7.33 – 7.13 (m, 1H), 7.02 (d, J = 1.1, 1H), 6.85 
(d, J = 1.2, 1H), 6.51 (s, 1H), 3.97 – 3.86 (m, 5H), 3.58 – 3.47 (m, 2H), 3.04 – 2.94 (m, 2H), 2.67 
(t, J = 7.4, 2H), 1.80 (dt, J = 11.3, 7.1, 2H), 1.68 (dt, J = 15, 7.1, 2H); 13C NMR (CDCl3, 125 
MHz) δ 171.0, 162.8, 159.4, 147.1, 141.4, 141.3, 128.5 (2C), 128.4 (2C), 126.1, 125.9, 119.2, 
115.4, 105.1, 102.7, 52.6, 46.0, 35.3, 30.8, 30.4, 28.4, 25.9; ESI-HRMS m/z 427.1421 (M – H, 
C23H25ClN2O4 requires 427.1425). 
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(S)-methyl 3-chloro-4,6-dihydroxy-2-(2-(1-(1-phenylethyl)-1H-imidazol-2-yl)ethyl)benzoate 
(33): Yield: 35 %; 1H NMR (CDCl3, 400 MHz) δ 7.28 – 7.17 (m, 3H), 7.01 (dd, J = 1.4, 1H), 
6.97 (m, 3H), 6.42 (s, 1H), 5.36 (q, J = 7.0, 1H), 3.71 (s, 3H), 3.42 (m, 2H), 2.84 (t, J = 8.2, 2H), 
1.74 (d, J = 7.0, 3H); 13C NMR (CDCl3, 125 MHz) δ 171.0, 162.8, 159.0, 147.5, 141.5, 141.4, 
129.0 (2C), 127.9, 126.2, 125.6 (2C), 116.7, 115.3, 105.3, 102.7, 54.8, 52.5, 30.7, 26.2, 22.5; 
ESI-HRMS m/z 399.111 (M – H, C21H21ClN2O4 requires 399.1112). 
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(R)-methyl 3-chloro-4,6-dihydroxy-2-(2-(1-(1-phenylethyl)-1H-imidazol-2-yl)ethyl)benzoate 
(34): Yield 42 %; 1H NMR (CDCl3, 400 MHz) δ 7.28 – 7.17 (m, 3H), 7.01 (dd, J = 1.4, 1H), 
6.97 (m, 3H), 6.42 (s, 1H), 5.36 (q, J = 7.0, 1H), 3.71 (s, 3H), 3.42 (m, 2H), 2.84 (t, J = 8.2, 2H), 
1.74 (d, J = 7.0, 3H); 13C NMR (CDCl3, 125 MHz) δ 171.0, 162.8, 159.0, 147.5, 141.5, 141.4, 
129.0 (2C), 127.9, 126.2, 125.6 (2C), 116.7, 115.3, 105.3, 102.7, 54.8, 52.5, 30.7, 26.2, 22.5; 
ESI-HRMS m/z 399.111 (M – H, C21H21ClN2O4 requires 399.1112). 
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methyl 3-chloro-4,6-dihydroxy-2-(2-(1-(pyridin-4-ylmethyl)-1H-imidazol-2-
yl)ethyl)benzoate (35): Yield: 40 %; 1H NMR (CDCl3, 400 MHz) δ 8.58 (dd, J = 4.5, 1.5, 2H), 
7.13 (d, J = 1.4, 1H), 6.96 (d, J = 6.0, 2H), 6.92 (d, J = 1.4, 1H), 6.47 (s, 1H), 5.19 (s, 2H), 3.89 
(s, 3H), 3.55 – 3.44 (m, 2H), 2.99 – 2.89 (m, 2H); 13C NMR (CDCl3, 125 MHz) δ 170.1, 162.5, 
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159.3, 150.1 (2C), 148.0, 145.8, 141.2, 127.2, 121.3 (2C), 120.3, 115.3, 105.4, 102.8, 52.6, 48.4, 
31.0, 26.0; ESI-HRMS m/z 386.0912 (M – H, C19H18ClN3O4 requires 386.0908). 
 
methyl 3-chloro-4,6-dihydroxy-2-(2-(1-(pyridin-3-ylmethyl)-1H-imidazol-2-
yl)ethyl)benzoate (36): Yield 48 %; 1H NMR (CDCl3, 400 MHz) δ 8.59 (dd, J = 4.6, 1.7, 1H), 
8.51 (d, J = 1.4, 1H), 7.40 – 7.30 (m, 2H), 7.11 (d, J = 1.3, 1H), 6.92 (d, J = 1.3, 1H), 6.50 (s, 
1H), 5.20 (s, 2H), 3.90 (s, 3H), 3.58 – 3.49 (m, 2H), 3.01 – 2.92 (m, 2H); 13C NMR (CDCl3, 125 
MHz) δ 170.5, 162.5, 158.8, 149.4, 148.0, 147.7, 141.4, 134.6, 132.1, 127.3, 124.1, 120.0, 115.1, 
105.6, 102.9, 52.6, 47.1, 31.1, 26.1; ESI-HRMS m/z 386.0903 (M – H, C19H18ClN3O4 requires 
386.0908). 
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methyl 3-chloro-4,6-dihydroxy-2-(2-(1-(pyridin-2-ylmethyl)-1H-imidazol-2-
yl)ethyl)benzoate (37): Yield: 45 %; 1H NMR (CDCl3, 400 MHz) δ 8.61 (d, J = 4.5, 1H), 7.69 
(td, J = 7.7, 1.7, 1H), 7.26 (dd, J = 7.3, 5.2, 1H), 7.11 (d, J = 1.3, 1H), 6.98 (d, J = 1.3, 1H), 6.85 
(d, J = 7.9, 1H), 6.49 (s, 1H), 5.29 (s, 2H), 3.88 (s, 3H), 3.58 – 3.45 (m, 2H), 3.06 – 2.91 (m, 
2H); 13C NMR (CDCl3, 125 MHz) δ 170.8, 162.7, 158.6, 156.0, 149.7, 147.9, 141.3, 137.5, 
127.0, 123.0, 120.7, 120.2, 115.1, 105.6, 102.8, 52.6, 51.2, 30.9, 26.0; ESI-HRMS m/z 386.0899 
(M – H, C19H18ClN3O4 requires 386.0908). 
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methyl 3-chloro-4,6-dihydroxy-2-(2-(1-(pyrimidin-5-ylmethyl)-1H-imidazol-2-
yl)ethyl)benzoate (38): Yield; 45 %; 1H NMR (CDCl3, 400 MHz) δ 9.19 (s, 1H), 8.54 (s, 2H), 
7.11 (d, J = 1.4, 1H), 6.91 (d, J = 1.4, 1H), 6.48 (s, 1H), 5.20 (s, 2H), 3.89 (s, 3H), 3.55 – 3.44 
(m, 2H), 3.02 – 2.92 (m, 2H); 13C NMR (CDCl3, 125 MHz) δ 169.1, 161.4, 157.6, 157.5, 154.4 
(2C), 146.7, 140.1, 128.9, 126.6, 118.7, 114.0, 104.8, 102.0, 51.6, 44.0, 30.1, 25.1; ESI-HRMS 
m/z 387.0861 (M – H, C18H17ClN4O4 requires 387.0860). 
Cl
HO OH
O
O
NN
O
 
methyl 3-chloro-4,6-dihydroxy-2-(2-(1-(4-methoxybenzyl)-1H-imidazol-2-yl)ethyl)benzoate 
(39): Yield 33%; 1H NMR (CDCl3, 400 MHz) δ 7.19 (m, 3H), 7.10 (d, J = 1.3, 1H), 6.93 (m, 
2H), 6.64 (s, 1H), 5.22 (s, 2H), 3.89 (s, 3H), 3.79 (s, 3H), 3.52 (dd, J = 9.0, 7.0, 2H), 3.10 (m, 
2H); 13C NMR (CDCl3, 125 MHz) δ 171.2, 162.2, 160.6, 158.9, 147.5, 141.6, 129.7 (2C), 128.8, 
123.9, 121.7, 115.1 (2C), 115.0, 108.2, 103.6, 55.6, 53.1, 50.1, 31.0, 26.1; ESI-HRMS m/z 
415.1061 (M – H, C21H21ClN2O5 requires 415.1061). 
NN
Cl
HO OH
OMe
O
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methyl 3-chloro-2-(2-(1-ethyl-1H-imidazol-2-yl)ethyl)-4,6-dihydroxybenzoate (40): Yield: 
43 %; 1H NMR (MeOH, 500 MHz) δ 6.91 (2, 1H), 6.77 (s, 1H), 6.12 (s, 1H), 3.82 (q, J = 7.3 Hz, 
2H), 3.73 (s, 3H), 3.30–3.33 (m, 2H), 2.84–2.87 (m, 2H), 1.24 (t, J = 7.3 Hz, 3H); 13C NMR 
(MeOH, 125 MHz) δ; 172.4, 163.1, 154.7, 148.6, 141.3, 135.1, 127.3, 119.9, 104.6, 101.3, 52.4, 
41.6, 32.0, 27.3, 16.5; ESI-HRMS m/z 323.0797 (M – H, C15H16ClN2O4 requires 323.0799). 
 
methyl 3-chloro-4,6-dihydroxy-2-(2-(1-isobutyl-1H-imidazol-2-yl)ethyl)benzoate (41): 
Yield: 42 %; 1H NMR (MeOH, 500 MHz) δ 7.02 (s, 1H), 6.91 (s, 1H), 6.39 (s, 1H), 3.87 (s, 3H), 
3.70 (d, J = 7.5 Hz, 2H), 3.32–3.37 (m, 2H), 2.96–2.99 (m, 2H), 1.92–2.05 (m, 1H), 0.91 (d, J = 
6.7 Hz, 6H); 13C NMR (MeOH, 125 MHz) δ 171.5, 161.1, 160.4, 148.7, 141.4, 126.9, 121.4, 
115.6, 109.3, 103.6, 54.0, 52.8, 31.7, 31.2, 27.4, 20.1 (2C); ESI-HRMS m/z 351.1115 (M – H, 
C17H20ClN2O4 requires 351.1112). 
 
 
methyl 3-chloro-4,6-dihydroxy-2-(2-(1-neopentyl-1H-imidazol-2-yl)ethyl)benzoate (42): 
Yield: 35 %; 1H NMR (MeOH, 500 MHz) δ 7.00 (s, 1H), 6.91 (s, 1H), 6.35 (s, 1H), 3.85 (s, 3H), 
3.70 (s, 2H), 3.35–3.38 (m, 2H), 2.98–3.01 (m, 2H), 0.96 (s, 9H); 13C NMR (MeOH, 125 MHz) δ 
171.7, 162.1, 161.6, 149.5, 141.4, 126.6, 122.5, 116.5, 107.9, 103.8, 57.6, 52.7, 34.3, 31.7, 28.1 
(3C), 27.8; ESI-HRMS m/z 365.1269 (M – H, C18H22ClN2O4 requires 365.1268). 
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methyl 3-chloro-4,6-dihydroxy-2-(2-(1-(2-methoxyethyl)-1H-imidazol-2-yl)ethyl)benzoate 
(43): Yield: 39 %; 1H NMR (MeOH, 500 MHz) δ 7.05 (d, J = 1.3 Hz, 1H), 6.88 (d, J = 1.2 Hz, 
1H), 6.27 (s, 1H), 4.05 (t, J = 5.2 Hz, 2H), 3.85 (s, 3H), 3.60 (t, J = 5.2 Hz, 2H), 3.40–3.42 (m, 
2H), 3.31 (s, 3H), 2.98–3.01 (m, 2H); 13C NMR (MeOH, 125 MHz) δ 172.2, 165.1, 162.6, 149.4, 
141.4, 127.1, 121.0, 118.1, 105.3, 104.4, 73.0, 59.2, 52.5, 46.7, 31.9, 27.4; ESI-HRMS m/z 
353.0902 (M – H, C16H18ClN2O5 requires 353.0904). 
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Chapter IV 
 
Evaluation of Proposed Grp94 Selective Inhibitors 
 
IV.1 Biological Roles of Grp94:  Implications for Grp94 Inhibition 
 As discussed previously, glucose-regulated protein 94 kDa (Grp94) was first identified as 
an induction product resulting from glucose deprivation.1  Subsequent studies identified Grp94 
as the endoplasmic reticulum (ER) paralog of heat shock protein 90 kDa (Hsp90).  Although 
potent Hsp90 inhibitors have been developed, no isoform selective inhibitors have been 
identified, other than NECA, which has proven to be an unacceptable starting point for small 
molecule development.  The highly homologous N-terminal binding domain has led the general 
research community to consider isoform selective inhibitors as an impractical venture.  However, 
analyses of the co-crystal structures has revealed obvious structural and mechanistic differences, 
specifically between Grp94 and cytosolic Hsp90 that can be exploited for inhibitor design.  
Identification of a selective Grp94 inhibitor would result in a paradigm shift for Hsp90 inhibition 
and help elucidate biological roles of Grp94.  Recently, siRNA, immunoprecipitation, and 
combinatorial Hsp90/Grp94 ATPase disruption has implicated Grp94 in cancer d the innate 
and adaptive immune responses.  Thus, small molecule selective Grp94 inhibitors have become 
desirable.  
IV.1.1 Grp94 and Cancer 
 The ER manifests its own response to cellular stress, a major component of which is the 
unfolded-protein response (UPR).2  Much like the heat shock response (HSR), which results in 
induction of cytosolic chaperones; activation of the UPR increases the concentration of resident 
ER chaperones.2  Therefore, not surprisingly, Grp94 levels are elevated in numerous 
malignancies.3  Known client proteins of Grp94, discussed in Chapter III, implicate Grp94 in the 
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maturation and trafficking of secretory and membrane bound proteins.4  Specific clients of Grp94 
that exhibit known roles in cancer progression include the insulin receptor substrate-1 (IRS-1), 
insulin-like growth factors I and II (IGF-1 and IGF-II), and integrins.4 
 IRS-1 is constitutively activated in numerous solid tumors including breast cancers, 
leiomyomas, Wilms' tumors, rhabdomyosarcomas, liposarcomas, leiomyosarcomas, and adrenal 
cortical carcinomas.5, 6  Tyrosine phyosphorylation of IRS-1 results in activation of the 
phospoinositide 3-kinase (PI3K) and mitogen-activated protein (MAP) kinase pathways; two 
pathways tied to oncogenesis.7-9  Furthermore, IRS-1 was found to play a key role in the 
constitutively activated β-catenin/Wnt signaling pathway, which contributes to transformation 
and cancer progression.5, 10  Blockade of the phosphorylation sites, through phenylalanine 
mutations, results in IRS-1 inactivation and a subsequent reduction in tumor growth.11  Recently, 
studies by Saitoh and colleagues have identified IRS-1 as a Grp94-deendent client protein12 and 
established Grp94 as a promising option for regulating aberrant IRS-1 function.  
 Another important class of client proteins dependent upon Grp94 is the integrin family.13, 
14  Intriguingly, not all integrins are Grp94-dependent, including β1 integrins which are Grp94 
independent.15  This intra-class specificity is a unique feature of Grp94 and further suggests 
Grp94 inhibition to yield a more acceptable toxicity profile than inhibitors targeting cytosolic 
Hsp90.  Integrins mediate adhesion between cells and their surrounding environment including 
other cell types or the extra cellular matrix.  Thus, it is not surprising that integrins regulate cell 
signaling, morphology, motility, and influence the cell cycle; all of which are features critical to 
intitiation, progression and metastasis of solid tumors.16  Therefore, indirect disruption of 
integrin formation, through Grp94 inhibition, represents a promising therapeutic venue. 
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 Of the client proteins dependent upon Grp94 for cancer progression, IGF-1 and IGF-II 
are the most studied.  Argon and colleagues have demonstrated the dependence of IGFs upon 
Grp94 and showed that upon Grp94 knockdown, pro-IGF intermediates are targeted for 
endoplasmic reticulum-associated degradation (ERAD) and mature IGF-I and IGF-II are not 
formed.17-20  Under normal cellular conditions, IGFs are tightly regulated, as the IGF signaling 
pathway is pro-growth and anti-apoptotic.  However under stressed conditions aberrant IGF 
signaling triggers a cascade of molecular events that can result in malignancy.21  Additionally, 
IGFs are known to activate signaling cascades through IRS-1 binding,22 thus intertwining two 
Grp94 clients to cancer progression. 
 Grp94 involvement in multiple facets of oncogenesis provides an impetus for the 
development of small molecule inhibitors.  Development of selective inhibitors may elucidate a 
novel anti-cancer target and thus provide a new class of cancer chemotherapeutics. 
IV.1.2 Grp94 and Inflammation  
 Beyond its role in the initiation and progression of cancer, Grp94 has been demonstrated 
to maintain an intricate role in immunomodulation.4, 23  Client proteins of Grp94 implicated in 
aberrant immuno-activity include major histocompatibility complex II (MHC II), 24 Toll-like 
receptors (TLR),14, 25 integrins,13, 14 interferon-γ (IFN-γ),26 and the p40 subunit of the interleukin-
12 (IL-12)27, 28 family of cytokines.  While all of these clients maintain roles in immunity, the 
affect on TLR activity has been most pursued. 
 TLRs are a component of the innate immune system responsible for recognizing foreign 
molecules present in the cellular milieu.29  Upon recognition of foreign material, TLRs trigger 
intracellular signaling cascades, which lead to immunoresponse through gene transcription.  
Immunoprecipitation and Grp94 knockout models have demonstrated the dependence of TLR1, 
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TLR2, TLR4 and TLR9 upon Grp94.13, 14  Inhibition of Grp94’s function leads to TLR retention 
in the ER and decreased surface presentation.  Expression levels of TLR mRNA remains 
unaffected by Grp94 inhibition, suggesting Grp94 is responsible for trafficking TLRs to the cell 
membrane.4  Thus, Grp94 represents a relevant therapeutic target for disease tates in which an 
exaggerated response to infection is evident including sepsis, rheumatoid arthritis, asthma and 
chronic autoimmune disorders.4, 29 
IV.2 Biological Evaluation of Proposed Grp94 Isoform Selective Inhibitors 
 After synthesizing the proposed Grp94 isoform selective inhibitors describ d in Chapter 
III, our attention turned towards their evaluation.  With no established protocol for the 
identification of Grp94 inhibitors, prior studies guided our desire to evaluate such analogs. 
IV.2.1 Anti-proliferative Activity 
 Previous reports have demonstrated Grp94 to be essential for embryonic development, 
but unlike cytosolic Hsp90, non-essential for mammalian cell culture viability.14, 30  Considering 
this observation, compounds 25–43 were evaluated against MCF-7 and SKBr3 cell lines, two 
breast cancer cell lines sensitive to Hsp90 inhibition.  Thus, if analogs 25–43 exhibit Hsp90 
inhibitory activity, cell death will be apparent.  As shown in Table 6, none of the analogs 
designed to be selective Grp94 inhibitors exhibited cytotoxicity against MCF-7 or SKBr3 cell 
lines at concentrations as high as 50 µM.  This mimics the activity of NECA, a known Grp94 
selective inhibitor, which was discussed in Chapter III.  As a control, cRDA (Chapter II) is 
included in Table 6, which manifests low micromolar activity against both MCF-7 and SKBr3 
cells lines.  This preliminary study provided the foundation for collab ration with the Nicchitta 
laboratory at Duke University to evaluate the inhibitors in a functional Grp94 assay.  
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IV.2.2 Inhibition of Toll-trafficking: A Grp94 Functional Assay 
 As discussed previously, TLRs are dependent upon Grp94 for their trafficking to the cell 
membrane.  In collaboration with the Nicchitta laboratory, we developed a functional Grp94 
assay utilizing human embryonic kidney cells (HEK293) stably transfected to express the Toll 
receptor, the Drosphilia melanogaster ortholog of human interleukin-1 receptor (Figure 38).  
This receptor is of the same superfamily as the human TLR2 and TLR4 receptors, establishing it 
as a viable surrogate for monitoring TLR expression.  In the presenc  of functional Grp94, the 
Toll receptor is trafficked to the cell membrane; however, in the absence of functional Grp94, the 
Toll receptor is sequestered intracellulary and not present on the cell membran .   
Table 6.  Anti-proliferative and Toll-trafficking results for compounds 
25–43.  IC50 values expressed in µM concentrations. 
 
Compound MCF-7 SKBr3 Grp94 
25 >50 >50 >50 
26 >50 >50 12.6 ± 1.0 
27 >50 >50 >50 
28 >50 >50 3.8 ± 0.2 
29 >50 >50 0.03 ± 0.02 
30 >50 >50 ND 
31 >50 >50 ND 
32 >50 >50 ND 
33 >50 >50 ND 
34 >50 >50 ND 
35 >50 >50 >50 
36 >50 >50 0.4 ± 0.3 
37 >50 >50 2.3 ± 1.6 
38 >50 >50 0.6 ± 0.1 
39 >50 >50 0.2 ± 0.2 
40 >50 >50 1.1 ± 0.7 
41 >50 >50 0.3 ± 0.1 
42 >50 >50 0.4 ± 0.1 
43 >50 >50 16.5 ± 1.2 
cRDA 6.3 ± 0.9 7.8 ± 0.2 8.5 ± 2.2 
NECA >50 >50 1.1 ± 0.2 
ND = not determined; compound exhibited <50% inhibition at 5 µM. 
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As expected, treatment of stably transfected HEK293 cells with Grp94 targeted siRNA 
resulted in inhibition of Toll membrane presentation (Figure 39).  Therefore, we proposed that a 
similar affect would be manifested 
by a small molecule Grp94 
inhibitor.  As shown in Table 6, 26, 
28, 29 and 36–43 exhibited 
inhibition of Toll-trafficking, 
indicative of Grp94 inhibition. 
des-Quinone Analogs 
 As discussed in Chapter III, 
the des-quinone RDA analogs (25–27, Figure 40) were designed to systematically evaluate the 
necessity of each moiety on the quinone ring for Hsp90 inhibition.  It was hypothesized that the 
functionalities on the quinone ring are necessary for Hsp90 inhibition and removal of such 
critical hydrogen-bonding functionalities should provide Grp94 selective inhibitors.   
 
Figure 38.  Functional Grp94 assay description.  HEK293 cells stably 
transfected with Toll are exposed to Grp94 target siRNA or small molecules and 
the presence of Toll expression is measured by confocal microscopy. 
Grp94 siRNA
treated (Grp94 )
Untreated
(Grp94 )
 
Figure 39.  Results of functional Grp94 Toll-
trafficking assay.  Cells treated with Grp94 targeted 
siRNA (left) and untreated cells (right). 
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 As predicted, removal of the 5-
carbonyl of RDA’s quinone ring (25), 
eliminated Hsp90 inhibitory activity up to 
concentrations as high as 50 µM.  
However, elimination of the 5-carbonyl 
failed to produce a Grp94 inhibitor, as 
shown in Table 6.  Subsequent removal of 
the 2-carbonyl (26) introduced micromolar Grp94 inhibition.  A representative depiction of the 
confocal microscopy results for 26, is shown in Figure 41.  As can be observed, Toll-expression 
on the cellular membrane is inhibited in a dose-dependent manner.  Although the IC50 value 
suggested by the graphic is 1–5 µM, it should be noted that IC50 calculations are conducted using 
at least 10 separate images, each containing 10–20 cells per concentration. 
Further manipulation of 
the RDA quinone ring via 
removal of the 4-methyl ether 
provided analog 27.  
Interestingly, 27 exhibited 
neither Hsp90 nor Grp94 
inhibitory activity at concentrations as high as 50 µM.  These results suggest that, for analogs 
based upon seco-RDA, the 4-methyl ether, or surrogate hydrogen-bond acceptor, is necessary for 
Grp94 inhibition.  Furthermore, the lack of activity for 25, suggests the presence of the 2-
hydroxy group, to inhibit the necessary conformation required for binding Grp94.  The 4-
methoxy functionality is proposed to hydrogen-bond with the free phenol of Tyr200 in the Grp94 
 
Figure 40.  Proposed analogs which lack key 
functionalities for yHsp82 binding. 
100 µM 5 µM 1 µM
Figure 41.  Representative confocal microscopy results for 
26 in the Toll-trafficking assay.   
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N-terminal nucleotide-binding pocket.  This is speculative, as docking studie  with this 
compound failed.  This modeling failure was expected however, becaus  in order to 
accommodate the interaction with Tyr200 the lid region of Grp94 must be displaced, which 
cannot be accomplished in the static representation of the protein in AutoDock31 or Surflex32, 33 
modeling programs.  Thus, to develop this class of Grp94 selective inhibitors further, analogs 
exploiting the interactions and spatial constraint of the 4-position will be synthesized.  
Additionally, it would be advantageous to acquire the co-crystal structure of 26, to account for 
the proposed lid displacement and provide a viable structure for subsequent modeling studies. 
Imidazole cis-Amide Bioisostere Analogs 
      The second hypothesis discussed in Chapter III was that cis- mide bioisosteric replacement 
of the amide bond, displayed by RDA, would provide selective Grp94 
inhibitors.  This proposal was a result of the analyses of 
RDA·yHsp90N and RDA·dGrp94N co-crystal structures.  
Furthermore, the binding data acquired for cRDA, demonstrates that 
cis-amide constraint results in a higher binding affinity for 
recombinant Grp94.  Thus, an imidazole linkage was hypothesized to 
provide a synthetically accessible scaffold capable of producing 
relevant analogs to test this hypothesis.  The first series of analogs synthesized were 28–32, 
which incorporated a phenyl substituted imidazole connected through varying tether linkages 
(Figure 42).  As observed in Table 6, only linker lengths of zero (28) and one (29) yielded 
significant Grp94 inhibition, with compound 29, exhibiting low-nanomolar activity.  This was in 
agreement with the initial Surflex docking studies reported in Chapter III, which suggest linker 
lengths of n = 0 or 1 exhibit superior Grp94 binding.  Compound 29 was hypothesized to project 
 
Figure 42:  Initial 
imidazole analogs 
with varying linker 
length. 
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into the NECA binding pocket and π-stack with either Phe199 or Tyr200.  The confocal 
microscopy results for 29 are shown 
in Figure 43.  Due to the superior 
Grp94 inhibitory activity, an 
expanded concentration range was 
evaluated.  Thus, compound 29 
served as our lead compound for 
further SAR development, leading 
to analogs 33–39 (Figure 44) and 
40–43 (Figure 45). 
As demonstrated in Table 6, 
steric bulk is not accommodated 
around the linker as introduction of 
a (S, 33) or (R, 34) methyl group 
dramatically decreased activity.  
 
Figure 44.  Imidazole analogs based upon 29.
 
Figure 43.  Representative confocal microscopy results for 29 in the 
Toll-trafficking assay.   
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This result was not surprising, as addition of a chiral center als the position of the aromatic 
ring.  Thus, the proposed π-stacking interactions with Phe199 and/or Tyr200 become hindered.  
Compound 35 also failed to elicit Grp94 inhibition even though it was hypothesized to hydrogen-
bond with Tyr200 similar to 26.  This was not entirely unexpected as electron-poor 4-pyridyl 
systems exhibit dramatically different properties than electron-rich anisoles; however, the 
inability of 35 to exhibit Grp94 inhibition suggests a different binding mode for the linear des-
quinone analogs than the constrained imidazole class of inhibitors.  This coincides with the 
alternative binding modes exhibited by trans- and cis-RDA when bound to Grp94, and suggests 
two exploitable scaffolds that can be optimized for Grp94 inhibition.  Thus, the trans-RDA 
conformation should be used as a model for des-quinone analogs.  Likewise, the cis-RDA 
conformation serves as a relevant model for development of the imidazole series.  Furthermore, 
the pyridine analogs 36–38, provide additional SAR data demonstrating the m-pyridine (36) to 
exhibit ~5-fold higher Grp94 inhibitory activity compared to the o-pyridine, 37.  Addition of an 
extra hydrogen-bond acceptor to yield pyrimidine 38 resulted in similar activity to 36, which 
suggests no additional hydrogen-bonding contacts are gained through the incorporation of an 
additional heteroatom.  The Grp94 inhibitory activity manifested by 36–38 is hypothesized to 
occur from beneficial binding interactions between the heterocyclic nitrogen and the protein 
backbone amides provided by Gly196 or Phe199, as shown in Figure 33 in Chapter III. 
 Incorporation of a p-methoxy group yielded the second-most active compound of this 
series, which manifests a Grp94 inhibitory IC50 value of ~200 nM.  Assuming a similar binding 
mode to 29, this suggests exploitable space surrounding the 4-position.  Thus, future analogs will 
aim to discern the size of this cavity. 
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 After evaluation of the synthesized benzylated 
imidazole analogs, compounds 40–43 (Figure 45), 
were evaluated in anti-proliferation and Toll-
trafficking assays.  As observed in Table 6, all of the 
analogs were active, with 41 exhibiting the most potent 
Grp94 inhibition.  However, none of the aliphatic 
analogs exhibited activity comparable to 29.  This 
suggests that π-stacking interactions outweigh 
hydrophobic interactions and contribute to the potency 
observed for 29.  Considering the results from the Toll-trafficking assay, comp und 29 was 
selected as a lead compound for further evaluation and was re-named KU-NG-1. 
IV.3 Biological Profile of KU-NG-1 
IV.3.1 Western Blot Confirmation for Lack of Hsp90 Inhibition 
 Although no cytotoxicity was observed for 
KU-NG-1 up to 100 µM, Western blot analysis was 
conducted on MCF-7 cell lysates treated with KU-
NG-1 to confirm the lack of Hsp90 inhibition.  As 
shown in Figure 46, no dose-dependent client 
protein degradation was observed upon treatment 
with KU-NG-1, as indicated by Akt and Raf levels.  
Furthermore, no induction of Hsp90 or Hsp70 
occurred, which is a hallmark of Hsp90 N-terminal inhibition, as willbe dicussed in detail in 
Chapter V.  Actin concentration is independent of Hsp90 and serves as a control. 
 
Figure 46.  Western blot analysis of 
MCF-7 cell lysates after treatment 
with KU-NG-1. 
 
 
Figure 45.  Alkyl-imidazoles 
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IV.3.2 NCI Cell Panel Profile                 
 Although Randow and Seed demonstrated a lack of dependency of immune cell-lines 
upon Grp94, very little evidence existed for transformed cell lines.  Our preliminary anti-
proliferative studies conducted with MCF-7 and SKBr3 breast cancer cells lines confirmed 
Randow and Seed’s findings; however, Grp94 expression is known to correlate with tumor 
growth and progression.  Therefore, KU-NG-1 was submitted to the National Cancer Institute 
(NCI) for evaluation against 60 cell-panel cytotoxicity assay in an attempt to elucidate the affect 
of Grp94 inhibition against various malignant cell cultures.  As shown in Figure 47, none of the 
cell-lines exhibited sensitivity to a 10 µM treatment of KU-NG-1.  This confirms Randow and 
Seed’s findings and provides evidence that cell culture viability, in general, is independent upon 
Grp94. 
 Interestingly, however, overexpression of Grp94 in numerous malignancies has been 
shown.  For instance, breast cancer carcinomas (HBL-100, MDA-MB-231, MCF-7, T47D, 
MDA-MB-453 and SkBR3) exhibit a ~3–5-fold increase of Grp94 in comparison to ormal 
breast tissue.  Furthermore, in conditions deprived of glucose, which mimics conditions observed 
in a poorly vascularized tumor, a 9-fold induction of Grp94 was observed.34 A ditionally, ductal 
and lobular invasive breast carcinomas show an increase in Grp94.35  A similar increase in Grp94 
expression is noted in gastric,36 pancreatic,37 colon,38 lung,39 esophageal40-42 and oral43 
malignancies; with Grp94 overexpression often correlating with poor r gnosis.  Thus, the 
expression pattern of Grp94 specific to tumors suggests a role for cancer progression and 
metastasis, even though transformed cell cultures lack dependency upon Grp94.   
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As discussed previously, Grp94 is responsible for the biological maturation of signaling 
molecules and secretory proteins, both of which are more important to a three-dimensional 
tumors than a cell-culture monolayer.  This may provide an explanation for the apparent 
dependence upon Grp94 for tumor growth and invasion even though cell cultures demonstrate 
 
Figure 47.  NCI 60 cell-panel cytotoxicity results for KU-NG-1. 
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lack of dependence.  Therefore, in order to validate Grp94 as a promising anti-cancer target, 
three-dimensional tumor models must be utilized to fully understand the role of Grp94 in cancer 
biology.  Recent research suggests the three-dimensional tumor environment to influence drug 
sensitivity.44, 45  Additionally, specific signaling pathways are dependent upon the three-
dimensional phenotype,45 thus providing rationale that artificial monolayer cell-cultures may not 
suffice for the evaluation of Grp94 inhibitors as anti-cancer chemotherapeutic agents. 
IV.3.3 Binding Data for KU-NG-1 
 In collaboration with Daniel 
Gewirth at the Hauptman-Woodward 
Medical Research Institute, the binding 
affinity of KU-NG-1 for recombinant 
Grp94 and Hsp90 was obtained utilizing isothermal calorimetry (ITC) and tryptophan 
fluorescence quenching (TFQ) techniques.  In the ITC experiments, the binding affinity of KU-
NG-1 was determined for the N-terminal truncates of canine Grp94 (dGrp94N) and human 
Hsp90 (hHsp90).  These truncates have been shown to bind ligands in a simlar fashion and with 
similar binding affinities as their full-length counterparts.  Furthermore, dGrp94N exhibits ~98% 
homology with hGrp94N and is an accepted surrogate for biochemical studies.46  Figure 48 
shows representative binding curves for ITC experiments.  As observed, KU-NG-1 shows 
reproducible binding curves for both dGrp94N and hHsp90N.  Surprisingly, KU-NG-1 binds 
hHsp90N with a ~2-fold higher binding affinity than dGrp94N, as shown in Table 7.  To confirm 
this observation, binding affinity was also determined with TFQ utilizing full-length dGrp94 and 
hHsp90.  As shown in Figure 49 and Table 7, the results verified a ~2-fold higher binding 
affinity for hHsp90 in comparison to dGrp94.   
Table 7.  Binding affinity data for KU-NG-1 
and Grp94 and hHsp90. 
Protein Method Affinity 
dGrp94N ITC 1.6 µM 
hHsp90N ITC 0.8 µM 
dGrp94 TFQ 0.25 µM 
hHsp90 TFQ 0.10 µM 
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Considering the preliminary evaluation of KU-NG-1, which demonstrated s lective 
Grp94 inhibitory activity, we were surprised by the 
binding affinity results.  The observed binding 
affinities may provide information about the 
physiologically relevant form of Grp94, as purified 
recombinant Grp94 may not represent a viable 
model for the species present under physiological 
conditions.  Interactions between Grp94, co-
chaperones, and/or co-factors in cells may result in a 
conformation of Grp94 more conducive to N-
 
Figure 48.  Representative ITC binding curves for KU-NG-1 binding to dGrp94N (left) and 
hHsp90N (right). 
 
Figure 49.  TFQ KU-NG-1 titration 
results for Grp94 and hHsp90.  
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terminal ligand binding; a conformation which is not populated in recombinant assays.  
Likewise, KU-NG-1 binds tightly to recombinant Hsp90; however it may not bind to the 
heteroprotein complex exhibited by Hsp90 in transformed cells.  Thus, the binding data paired 
with KU-NG-1’s cellular profile suggests a complex-induced selectivity.  Although Grp94 has 
been shown to interact with co-chaperones and co-factors (unpublished data), no heteroprotein 
complexes have been identified or isolated.  Therefore, studies that could verify this complex-
induced selectivity are not currently possible with recombinant assays. 
A second hypothesis for the observed discrepancy is that Grp94 inhibitors may exhibit a 
slow-tight binding profile due to the necessity for lid displacement.  The binding studies 
completed to date were conducted on a short time scale, and do not account for time-dependent 
inhibition.  Thus, necessary studies are ongoing and will address this hypothesis. 
IV.4 Future Directions and Concluding Remarks 
 The development of a Grp94 isoform selective inhibitor represents an uncharted territory, 
and therefore the utility of such an inhibitor has yet to be demonstrated.  To date, all experiments 
identifying Grp94 dependent processes or client proteins have been conducted with Grp94 
targeted siRNA or unselective Hsp90 inhibitors.  Thus, the biological profile f r Grp94 results 
from disruption of the protein at the pre-transcriptional level, or after combinatorial disruption of 
both Hsp90 and Grp94.  Considering the complex array of cellular responsibilities for Grp94 and 
the complex network involved with the mature chaperone, the only true mechanism to determine 
the utility of Grp94 inhibition is through the design of small molecule selective inhibitors. 
 Analysis of the Grp94 ATPase cycle can be utilized to explain the discrepancy between 
the binding and cellular data.  Upon binding client proteins, alterations in the tertiary structure 
arise, including changes to the N-terminal binding domain.47  Thus, it is plausible that the 
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conformation of the N-terminal binding pocket conducive to inhibitor binding is not revealed 
until client protein binding.  Furthermore, conformations of the Grp94 N-terminal binding pocket 
may be client specific.  Thus, Grp94 inhibitory scaffolds may disrupt specific clients, while not 
affecting others.  For example, the conformation of Grp94 N-terminal bi ding pocket induced 
upon binding TLR binding may not be reciprocated upon the binding of IGFs, thus, an inhibitor 
such as KU-NG-1 may only bind and inhibit the conformation of Grp94 necessary for TLR 
trafficking.  This leads to the proposal that small molecule Grp94 inhibitors can not only be 
designed, but can be manipulated to exhibit client specific affects.   
 As discussed in this chapter, we believe the first small molecule Grp94 inhibitor has been 
identified.  Utilizing structure-based design techniques in parallel with conformational 
constraints, we have identified two scaffolds exhibiting Grp94 inhibition, as demonstrated 
through a novel Toll-trafficking assay.  Development of a class of imidazole isosteres yielded 
nanomolar compounds, one of which, KU-NG-1, manifests ~ 30 nM activity.   
 Collaborations with the Gewirth laboratory have produced a co-crystal structure for KU-
NG-1 bound to Grp94N, which is undergoing the final stages of refinement.  Therefore, a clear 
picture of the interactions between KU-NG-1 and Grp94 will be availble, expediting the 
structure-based development of novel compounds.  The progression of Grp94 inhibitors relies 
opon the ability to develop relevant functional assays.  Development of such a says will help 
analyze the proposal that client-induced conformation drives inhibitor binding, and may provide 
evidence that client specific inhibitors can be developed.       
IV.5 Methods and Experimentals 
Anti-proliferation Assay:  MCF-7 and SKBr3 cells were maintained in a 1:1 mixture of 
Advanced DMEM/F12 (Gibco) supplemented with non-essential amino acids, L-glutamine (2 
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mM), streptomycin (500 µg/mL), penicillin (100 units/mL), and 10% FBS. Cells were grown to 
confluence in a humidified atmosphere (37 °C, 5% CO2), seeded (2000/well, 100 µL) in 96-well 
plates, and allowed to attach overnight. Compound or geldanamycin at varying concentrations in 
DMSO (1% DMSO final concentration) was added, and cells were returned to the incubator for 
72 h.  At 72 h, the number of viable cells was determined using an MTS/PMS cell proliferation 
kit (Promega) per the manufacturer’s instructions. Cells incubated in 1% DMSO were used as 
100% proliferation, and values were adjusted accordingly. IC50 values were calculated from 
separate experiments performed in triplicate using GraphPad Prism. 
 
Western Blot Analysis:  MCF-7 cells were cultured as described previously48 and treated with 
various concentrations of drug, GDA in DMSO (1% DMSO final concentration), or vehicle 
(DMSO) for 24 h.  Cells were harvested in cold PBS and lysed in RIPA lysis buffercontaining 1 
mM PMSF, 2 mM sodium orthovanadate, and protease inhibitors on ice for 1 h.  Lysates were 
clarified at 1400 g for 10 min at 4 ºC.  Protein concentrations were determined by using the 
Pierce BCA assay kit per the manufacturer’s instructions.  Equal amounts of protein (20 µg) 
were electrophoresed under reducing conditions, transferred to a nitrocellulose membrane, and 
immunoblotted with the corresponding specific antibodies.  Membranes were incubated with an 
appropriate horseradish peroxidase-labeled secondary anti-body, developed with 
chemiluminescent substrate, and visualized. 
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Chapter V 
 
The Design, Synthesis and Biological Evaluation  
of a Pro-mustard Irreversible Alkylator of Hsp90 
 
V.1 Rationale for an Irreversible Hsp90 Alkylator 
As discussed in Chapter I, numerous detriments exist with current Hsp90 inhibitors 
undergoing clinical evaluation.  While many of these complications arise from pan-inhibition of 
all four Hsp90 isoforms, biological events, such as heat shock induction, are believed inherent to 
N-terminal Hsp90 inhibition.  This is a consequence of heat shock factor-1 (HSF-1) release and 
subsequent binding to the heat shock element (HSE), which induces transcription of the heat 
shock genes.1, 2  Under non-stressed conditions, Hsp90 binds HSF-1, preventing its function as a 
transcription factor (1, Figure 50).3  In contrast, under stressed conditions, such as the 
accumulation of denatured proteins, HSF-1 is released from Hsp90 (2).  Subsequent trimerization 
 
Figure 50.  Heat shock factor-1 mediated induction of the heat shock response. 
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and phosphorylation of HSF-1 renders the active HSF-1 transcription factor (3).2-4  This 
phosphorylated trimer translocates into the nucleus and binds the HSE to prom te transcription 
of HSP genes (4).2-4  N-terminal Hsp90 inhibitors also stimulate HSF-1 release, and induction of 
the heat shock response (HSR).5  Thus, while client proteins are degraded upon Hsp90 inhibition 
(5), the intracellular concentration of Hsp90 and various other anti-apoptotic chaperones (Hsp70, 
Hsp40 and Hsp27) are induced.  This pro-survival response, specifically inductio  of the target 
protein, Hsp90, has resulted in dosing and scheduling issues with Hsp90 inhibitors in the clinic.6  
Therefore, a solution to this problem may lie in an Hsp90 inhibitor that results in synchronous 
degradation of the chaperone alongside client proteins.  Although HSF-1 release and heat shock 
induction would still occur, a significant concentration of Hsp90 would succumb to proteasome 
degradation, culminating in an overall stagnant intracellular Hsp90 concentration. 
V. 2 Design of 17-CEAG   
 Studies resulting from our laboratory and others have revealed the hydroquinone of 
GDA, as compared to the quinone, to exhibit greater activity against transformed cells.7  This 
finding resulted in subsequent studies that identified NADH quinone oxidoreductase (NQO1) as 
the enzyme responsible for reduction of the quinone to the more active hydroquinone.8-10  
Xenobiotic metabolism is a secondary function of NQO1, as its primary biological role is to 
maintain a reduced antioxidant state of coenzyme Q (CoQ) in the mitochondrial electron 
transport chain.11-13  Nonetheless, NQO1’s secondary role in xenobiotic metabolism is one of 
importance, as numerous quinone containing molecules are known to undergo NQO1 mediated 
reduction.14   
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Previous studies have shown that 17-amino substitutions 
to the GDA scaffold maintain high affinity for Hsp90.15, 16  The 
dependence of ansamycin analogs upon NQO1 for reduction, 
provided a novel approach towards the development of a 
mechanism-based irreversible Hsp90 inhibitor that contained a 
pro-mustard functionality, namely 17-chloroethylamino-17-
demethoxygeldanamycin (17-CEAG, Figure 51).  This compound was previously patented in 
2006 for photolabeling purposes; however, alkylation studies were never disclosed.17   
In the quinone oxidation state, the pendent nitrogen lone-pair is delocalized into the 
quinone π-system.  Upon reduction by NQO1 the electron-deficient quinone is tran formed into 
an electron-rich hydroquinone.  Thus, delocalization of the nitrogen lone pair is unfavorable, 
rendering the electrons reactive and available to displace the appnded chlorine via an 
intramolecular SN2 mechanism (Figure 52).
18, 19  The resulting aziridinium ion then provides the 
requisite functionality for Hsp90 alkylation upon binding.18, 19  As expected, Surflex20, 21 
molecular modeling studies suggest the 17-CEAG aziridine to bind Hsp90 similarly to 17-AAG 
with the nucleophilic Lys44 poised for attacked onto the aziridinium (Figure 53).  Once 
alkylated, the Hsp90 machinery should become ubiquitinylated and subsequently degraded by 
 
Figure 51.  Structure of 
17-CEAG. 
 
Figure 52.  Reduction/activation of 17-CEAG via NQO1.  Electron flow depicted by 
green (favorable) and red (unfavorable) arrows.  Electronic nature of quinone 
oxygens depicted with electron withdrawal in blue and electron donation in orange. 
 135
the proteasome.22  This degradation is 
proposed to counteract induction caused by 
HSF-1 release; thus, leading to a negligible 
change in Hsp90 concentration. 
V.3 Synthesis of 17-CEAG 
 In accordance with previous 17-
amino-17-demethoxygeldanamycin 
derivatives,23 17-CEAG was synthesized in 
one step from GDA (Scheme 7).  Upon 
treatment of GDA with 2-chloroethylamine 
hydrochloride and diisopropylethylamine 
(DIPEA) in dichloromethane (DCM) at room temperature, nucleophilic displacement of the 17-
methyl ether resulted in the desired compound, 17-CEAG, in 90% yield. 
V.4 Biological Evaluation of 17-CEAG 
 Upon synthesis of 17-CEAG, biological evaluation was undertaken in collaboration with 
David Ross’ laboratory at The University of Colorado Denver to elucidate the activity profile.   
 
 
Figure 53.  Overlay of 17-CEAG aziridine 
(yellow) and 17-AAG (magenta) in the N-
terminal Hsp90 ATP-binding pocket.  
 
Scheme 7.  Synthesis of 17-CEAG. 
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V.4.1 NQO1 Reduction Dependence 
 NQO1 (also known as DT-diaphorase) is an obligate 2-electron transfe  flavoprotein that 
catalyzes the reduction of quinones to hydroquinones.12-14, 24  In 1999, researchers at the National 
Cancer Institute (NCI) aimed to determine the metabolic fate of ansamycin-based Hsp90 
inhibitors in hopes of elucidating toxicity issues associated with th s class of inhibitors.  Results 
suggested 17-AAG to be a substrate for NQO1 reduction.8  Furthermore, the reduced form of 17-
AAG, 17-AAGH2, exhibited a 32-fold increase in growth inhibitory activity against various cell-
lines.8  These studies demonstrated that 17-amino substituted ansamycin analogs are substrates 
for NQO1. 
 In accordance with the studies completed at NCI, 17-CEAG was shown to be dependent 
upon NQO1 for reduction to 17-CEAGH2 (Figure 54).  Incubation of 17-CEAG with NADH in 
potassium phosphate buffer was not sufficient to reduce the parent compound, and only the 
quinone species was present by HPLC analysis.  However, upon addition of NQO1 to the 
reaction mixture, rapid reduction occurred revealing near complete conversion to 17-CEAGH2. 
 
Figure 54.  Dependence upon NQO1 for reduction of 17-CEAG to 17-CEAGH2.  Incubation 
of 17-CEAG without NQO1 (left) and incubation of 17-CEAG in the presence of NQO1 
(right). 
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 In order to further verify the 
dependence upon NQO1 for formation 
of 17-CEAGH2, a small molecule 
irreversible NQO1 inhibitor, ES936, 
was incubated with NQO1 prior to 
addition of 17-CEAG.  As observed in 
Figure 55, ES936 completely abolished 
the reduction of 17-CEAG, as only the 
quinone form was present.  Results from these experiments clearly d monstrate that 17-CEAG is 
an NQO1 substrate and is dependent upon the reductase for conversion to 17-CEAGH2. 
 V.4.2 Anti-proliferative Activity 
 Previous studies suggest mammalian cell cultures to be more sensitive to the 
hydroquinone form of ansamycins.7  Furthermore, research has shown cell lines exhibiting 
higher concentrations of NQO1 are more sensitive to ansamycin treatment than cell lines 
deficient in NQO1.25, 26  To parallel previously studies, 17-CEAG was evaluated for anti-
proliferative activity against two isogenic cell lines: 1) MDA-468 breast cancer cells, which are 
NQO1 null as a consequence of a genetic polymorphism; and 2) MDA-468 (NQO1) cells which 
have been stably transfected to express high levels of NQO1. 
Figure 55.  Affect of NQO1 inhibitor, ES936, on 
the reduction of 17-CEAG. 
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 Firstly, the intracellular concentration of each 17-CEAG species was measured via HPLC 
analysis.  As shown in Figure 56, the only species present in NQO1 null cells was 17-CEAG.  
Additionally, the size of the peak in the HPLC trace demonstrates poor membrane permeabililty 
for the quinone species, consistent with previous studies.  Other than improved binding 
interactions with the Hsp90 N-terminal binding pocket, superior intracellular sequestration and 
thus higher intracellular concentrations have been proposed as reasons for the improved activity 
manifested by hydroquinone ansamycin species.7  Therefore, it was not surprising that cells 
expressing high levels of NQO1, exhibited a high intracellular concentration of 17-CEAGH2, 
which further supports that ansamycin 
hydroquinone species are more efficiently 
sequestered intracellulary than the quinone 
counterparts. 
 In addition, as observed in Table 8, 17-
CEAG manifested ~12-fold higher anti-
proliferative activity against MDA-468 (NQO1) 
cells than MDA-468 cells.  This ~12-fold increase in activity was also observed upon treatment 
 
Figure 56.  Oxidation state of 17-CEAG in MDA-468 (NQO1 null) cells (left) and MDA-468 
(NQO1) cells (right). 
Table 8.  Anti-proliferation activity of 
17-CEAG against MDA-468 and MDA-
468 (NQO1) cell-lines. 
 
Compound MDA-468 
IC50 (µM) 
MDA-468 
(NQO1) 
IC50 (µM) 
17-AAG 10.05 0.86 
17-CEAG 4.53 0.37 
MTT cytotoxicity assay 
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of the cell-lines with 17-AAG, which is comparable to activity exhibited by other NQO1 
dependent ansamycins. 
V.4.3 Western Blot Analyses 
 To confirm cytotoxic activity resulted from Hsp90 inhibition, Western Blot analyses were 
conducted on MDA-468 (NQO1) cell lysates after treatment with 17-CEAG and 17-AAG, both 
in the presence and absence of NQO1 inhibitor ES936.  As shown in Figure57, Akt, a client of 
Hsp90, demonstrated a dose-dependent degradation in the presence of both 17-AAG and 17-
CEAG, which is indicative of Hsp90 inhibition.  As discussed previously, inhib tion of Hsp90 
with N-terminal inhibitors results in HSF-1 mediated heat shock induction.  In the presence of a 
reversible Hsp90 inhibitor (17-AAG), dissociation of the inhibitor from Hsp90 occurs, allowing 
the chaperone to continue the protein folding cycle.  Thus, no Hsp90 degradation occurs to 
counteract the HSF-1 mediated induction, which results in an overall increase in Hsp90 
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Figure 57.  Western Blot analyses of MDA-468 (NQO1) cell lysates after 
treatment with 17-AAG and 17-CEAG; both in the presence and absence of 
ES936.  Concentrations expressed as µM. 
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concentration.  This phenomenon is 
observed after treatment of MDA-468 
(NQO1) cells with 17-AAG, and is 
illustrated in Figure 58.  In contrast, 
upon treatment of MDA-468 (NQO1) 
cells with 17-CEAG, client protein 
degradation occurred at similar 
concentrations to 17-AAG (10–100 
nM); however, Hsp90 levels remained 
constant (Figure 59) while Hsp70 levels increased.  As expected, in the presence of ES936, 
Hsp90 induction is observed.  This can be attributed to inhibition of NQO1, which mitigates the 
formation of 17-CEAGH2, thus eliminating the alkylation of Hsp90.  However, at high 
concentrations of 17-CEAG, occupation of NQO1 by 17-CEAG prevents inhibition of the 
enzyme by ES936.  Thus, 17-CEAG reduction occurs and subsequent Hsp90 alkylation results in 
regression of Hsp90 concentration to 
control levels.  Therefore, Western 
Blot analyses confirm the hypothesis 
that NQO1 dependent formation of 17-
CEAGH2 leads to Hsp90 alkylation 
and subsequent degradation, resulting 
in a negligible overall change in 
Hsp90 levels.  
   
 
Figure 58.  Densitometry results of the Western 
Blots from MDA-468 (NQO1) cell lines after 
treatment with 17-AAG. 
 
Figure 59.  Densitometry results of the Western 
Blots from MDA-468 (NQO1) cell lines after 
treatment with 17-CEAG. 
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V.5 Future Studies and Concluding Remarks 
 Prior to publishing the profile for 17-CEAG, more studies are needed.  Firstly, Hsp90 
alkylation studies must be completed to ensure protein modification is ccuring.  Preliminary 
alkylation studies have failed; however condition optimization is ongoing with the Desaire 
Laboratory at The University of Kansas.  Alkylation was hypothesized to be the rate-limiting 
experiment, as facile auto-oxidation back to the quinone species in vitro has been reported 
previously with 17-amino ansamycin inhibitors, which would mitigate the ability to alkylate the 
protein.  Secondly, Western Blot analyses need to be conducted in the presence of a proteasome 
inhibitor, such as bortezomib to verify the mechanism of Hsp90 degradation upon alkylation.  If 
Hsp90 alkylation leads to proteasome mediated degradation, then inhibition of the proteasome 
should reveal similar Hsp90 induction as seen with 17-AAG.  Both of these studies are 
imperative in confirming the mechanism of action for 17-CEAG.  
 As discussed in this chapter, a pro-mustard ansamycin-based Hsp90 inhibitor has been 
designed and synthesized.  Knowledge of NQO1 based reduction of this class of Hsp90 inhibitor 
has provided rationale for the development of 17-CEAG.  Our studies have shown 17-CEAG to 
be dependent upon NQO1 for reduction to 17-CEAGH2, dependent upon NQO1 for anti-
proliferative activity, and to exhibit dose-dependent Hsp90 client pro ein degradation while 
failing to increase Hsp90 levels up to ~1.0 µM.  Therefore, 17-CEAG has exhibited the 
biological profile proposed at the onset of studies and represents a promising lead for the first 
pro-mustard Hsp90 alkylating agent.    
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V.6 Methods and Experimentals 
 
(4E,6Z,8S,9S,10E,12S,13R,14S,16R)-19-((2-chloroethyl)amino)-13-hydroxy-8,14-
dimethoxy-4,10,12,16-tetramethyl-3,20,22-trioxo-2-azabicyclo[16.3.1]docosa-
1(21),4,6,10,18-pentaen-9-yl carbamate (17-CEAG): To a solution of 2-chloroethylamine 
hydrochloride (105 mg, 0.9 mmol, 10 equiv.) and N.N-diisopropylethylamine (DIPEA, 151 mg, 
1.17 mmol, 13 equiv.)  in anhydrous DCM under argon at 25 ˚C, was added geldanamycin 
(GDA, 50 mg, 0.09 mmol).  The reaction was stirred under argon at 25 ˚C for ~18 h.  After 
complete conversion of GDA, as observed by TLC, the solvent was removed in acuo and the 
residue subjected to flash chromatography utilizing 97:3 (DCM:MeOH) as the eluent.  The 
desired product was isolated as a purple amorphous solid (49 mg, 90% yield). 1H NMR (CDCl3, 
500 MHz) δ 9.09 (s, 1H), 7.29 (s, 1H), 6.94 (bd, J = 11.5 Hz, 1H), 6.56 (ddd, J = 11.5 Hz, 11.0 
Hz, 1.0 Hz, 1H), 6.35 (bt, J = 5.0 Hz, 1H), 5.87 (bd, J = 9.5 Hz, 1H), 5.85 (bdd, J = 11.0 Hz, 
10.0 Hz, 1H), 5.18 (s, 1H), 4.72 (bs, 2H), 4.30 (bd, J = 10.0 Hz, 1H), 4.03 (bs, 1H), 3.94–3.83 
(m, 2H), 3.75–3.67 (m, 2H), 3.56 (ddd, J = 9.0 Hz, 6.5 Hz, 2.0 Hz, 1H), 3.43 (ddd, J = 9.0 Hz, 
3.0 Hz, 3.0 Hz, 1H), 3.35 (s, 3H), 3.26 (s, 3H), 2.73 (dqd, J = 9.5 Hz, 7.0 Hz, 2.0 Hz, 1H), 2.70 
(d, J = 14.0 Hz, 1H), 2.24 (dd, J = 14.0 Hz, 11.0 Hz, 1H), 2.01 (bs, 3H), 1.78 (d, J = 1.0 Hz, 3H), 
1.80–1.75 (m, 2H), 1.75–1.68 (m, 1H), 1.00–0.96 (m, 6H); 13C NMR (CDCl3, 125 MHz) δ 183.8, 
181.2, 168.3, 155.9, 144.7, 140.8, 135.9, 135.0, 133.6, 132.9, 127.0, 126.5, 110.0, 109.1, 81.6, 
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81.4, 81.2, 72.7, 57.1, 56.7, 46.9, 42.7, 35.1, 34.4, 32.4, 28.8, 23.0, 12.8, 12.6, 12.5; ESI–HRMS 
630.2548 (M + Na, C30H42ClN3ONa requires 630.2558). 
 
Western Blot Analyses: MDA468 or MDA468/NQ16 were maintained in RPMI 1640 media 
supplemented L-glutamine (2 mM), streptomycin (500 µg/mL), penicillin (100 units/mL), and 
10% FBS. Cells were grown to confluence in a humidified atmosphere (37 °C, 5% CO2), seeded 
(3x105/well, 2 mL) in 6-well plates, and grown to 60% confluency prior to dosing. Cells were 
then treated with various concentrations of 17-CEAG or 17-AAG in DMSO (1% DMSO final 
concentration), or vehicle (DMSO) for 24 h. Cells were harvested in cold PBS and lysed in 
mammalian protein extraction reagent (MPER, Pierce) containing protease inhibitors (Roche) on 
ice for 1 h. Lysates were clarified at 14,000g for 15 min at 4° C. Protein concentrations were 
determined using the Pierce BCA protein assay kit per the manufacturer’s instructions. Equal 
amounts of protein (5 µg) were electrophoresed under reducing conditions, transferred to a 
PVDF, and immunoblotted with the corresponding specific antibodies. Membranes were 
incubated with an appropriate horseradish peroxidase-labeled secondary antibody, developed 
with a chemiluminescent substrate, and visualized. Densitometry was performed using ImageJ 
“Gels” tool. 
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